ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 1 .
CLINICAL STUDY PROTO COL  
Protocol Title:  
A Phase 2, randomized, active ‑controlled, observer -blind, dose -ranging study to evaluate the 
safety, reactogenicity , and immunogenicity of mRNA vaccine candidate variations in healthy 
adults 18  to 49 years of ag e. 
Protocol Number:  mRNA -CRID -004 
Date : 12 Apr 2023  
Compound : mRNA -1010 variations  
Brief Title:  
Study to evaluate the safety, reactogenicity , and immunogenicity of mRNA vaccine candidate 
variations in healthy adults 18 to 49 years of age . 
Study Phase : Phase 2  
Sponsor Name:  
[CONTACT_14358], Inc . 
Legal Registered Address:  
200 Technology Square  
Cambridge, MA [ZIP_CODE]  
Regulatory Agency Identifier Number(s) : 
Registry  ID 
FDA  IND 028259  
Approval Date:  12-Apr-2023  
Sponsor Signatory:  
See e -Signature [CONTACT_14359].  
 
 
 Date  
Sponsor Signatory  and Contact [CONTACT_9249].  
NCT #: [STUDY_ID_REMOVED]
[COMPANY_003]
ModernaTX, Inc.  
mRNA -CRID -[ADDRESS_504083] read and understood all sections of the protocol entitled “ A Phase 2, randomized, 
active -controlled, observer -blind, dose -ranging study to evaluate the safety, reactogenicity , and 
immunogeni city of mRNA vaccine candidate variations in healthy adults 18  to 49 years of age ” 
dated [ADDRESS_504084] the clinical investigation in 
accordance with the current Protocol, the International Council for Harmonisation (ICH) of 
Technical Requirements for Registration of Pharmaceuticals for Human Us e, E6(R2) Good 
Clinical Practice (GCP) Guidance , and all applicable local and country regulations. I will not 
make changes to the protocol before consulting with ModernaTX, Inc. or implement protocol 
changes without IRB/IEC approval except to eliminate an immediate risk to participants.  
I agree to administer study treatment only to participants under my personal supervision or the 
supervision of a Subinvestigator . I will not supply study treatment to any person not authorized 
to receive it. I also agree tha t persons debarred from conducting or working on clinical studies by 
[CONTACT_14292] a partnership in which the Sponsor is involved. I will immediately disclose it in writi ng to the 
Sponsor if any person who is involved in the study is debarred, or if any proceeding for 
debarment is pending, or, to the best of my knowledge, threatened.  
I will not disclose confidential information contained in this document including particip ant 
information, to anyone other than the recipi[INVESTIGATOR_14251]/IEC. I agree 
to ensure that this information will not be used for any purpose other than the evaluation or 
conduct of the clinical investigation without the prior writte n consent from ModernaTX, Inc. I 
will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from ModernaTX, Inc.  
The signature [CONTACT_14360] l be conducted 
according to all stipulations of the protocol, including statements regarding confidentiality, and 
according to local legal and regulatory requirements, regulations, and ICH E6(R2) GCP 
guidelines.  
 
Signature [CONTACT_789]    [INVESTIGATOR_56779], Inc.  
mRNA -CRID -[ADDRESS_504085] OF ABBREVIATION S ................................ ................................ ................................ .......... 8 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 10 
1.1. Protocol Synopsis  ................................ ................................ ................................ .......10 
1.2. Schema  ................................ ................................ ................................ ........................ 12 
1.3. Schedule of Activities  ................................ ................................ ................................ .13 
2. INTRODUCTION  ................................ ................................ ................................ ......17 
2.1. Study Rationale  ................................ ................................ ................................ ........... 17 
2.2. Background  ................................ ................................ ................................ ................. 17 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 17 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ......... 17 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ .....18 
2.3.3. Overall Benefit/Risk Conclusion  ................................ ................................ ................ 18 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 19 
4. STUDY DESIGN  ................................ ................................ ................................ .......20 
4.1. Overall  Design  ................................ ................................ ................................ ............ 20 
4.2. Scientific Rationale for Study Design  ................................ ................................ ........ 21 
4.3. Justification for Dose  ................................ ................................ ................................ ..21 
4.4. End-of-Study Definition  ................................ ................................ ............................. 21 
5. STUDY POPULATION  ................................ ................................ ............................. 22 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 22 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......23 
5.3. Screen Failures  ................................ ................................ ................................ ............ 25 
5.4. Criteria for Temporarily Delaying Administration of Study Intervention  ................. 25 
6. STUDY INTERVENTIONS AND CONCOMITANT THER APY ........................... 26 
6.1. Study Interventions Administered  ................................ ................................ .............. 26 
6.2. Preparation, Handling, Storage, and Accountability  ................................ .................. 27 
6.3. Assignment to Study Intervention  ................................ ................................ .............. 28 
6.4. Blinding  ................................ ................................ ................................ ...................... 28 
6.5. Study Intervention Compliance  ................................ ................................ .................. 28 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 4 6.6. Dose Modification  ................................ ................................ ................................ ......29 
6.7. Continued Access to Study Intervention after End -of-Study  ................................ .....29 
6.8. Treatment of Overdose  ................................ ................................ ............................... 29 
6.9. Prior and Concomitant Therapy  ................................ ................................ .................. 29 
6.9.1.  Concomitant Medications and Therapi[INVESTIGATOR_014]  ................................ ................................ ...29 
6.9.2.  Conco mitant Medications and Vaccines that May Lead to the  Elimination of 
a Participant from Per Protocol Analyses ................................ ................................ ....30 
7. DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  ................................ .......32 
7.1. Discontinuation of Study Intervention ................................ ................................ ........ 32 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ........... [ADDRESS_504086]  ................................ ................................ ............. 42 
[IP_ADDRESS].  Anaphylaxis  ................................ ................................ ................................ ................ 43 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 5 [IP_ADDRESS].  Myocarditis and/or Pericarditis  ................................ ................................ ................... 43 
8.5. Pharmacokinetics  ................................ ................................ ................................ ........ 44 
8.6. Pharmacodynamics  ................................ ................................ ................................ .....44 
8.7. Genetics  ................................ ................................ ................................ ...................... 44 
8.8. Biomarkers  ................................ ................................ ................................ .................. 44 
8.9. Health Economics OR Medical Resource Utilization and Health Economics  ........... 44 
9. STATISTICAL CONSIDER ATIONS  ................................ ................................ .......45 
9.1. Blinding and Responsibility for Analyses  ................................ ................................ ..45 
9.2. Statistical Hypotheses  ................................ ................................ ................................ .45 
9.3. Sample Size Determination  ................................ ................................ ........................ 46 
9.4. Analysis Sets  ................................ ................................ ................................ ............... 46 
9.5. Statistical Analyses  ................................ ................................ ................................ .....46 
9.5.1.  Baseline Characteristics and Demographics  ................................ ............................... 47 
9.5.2.  Immunogenicity Analyses  ................................ ................................ .......................... 47 
9.5.3.  Safety Analyses  ................................ ................................ ................................ .......... 47 
9.5.4.  Exploratory Analyses  ................................ ................................ ................................ ..48 
9.6. Planned Analyses  ................................ ................................ ................................ ........ 48 
9.6.1.  Interim Analysis  ................................ ................................ ................................ .......... 48 
9.6.2. Final Clinical Study Report  ................................ ................................ ........................ 48 
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..49 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  .................... 49 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ......49 
10.1.2.  Financial Disclosure  ................................ ................................ ................................ ...49 
10.1.3.  Informed Consent Process  ................................ ................................ .......................... 50 
10.1.4.  Recruitment Strategy  ................................ ................................ ................................ ..50 
10.1.5.  Data Protection  ................................ ................................ ................................ ........... 50 
10.1.6.  Committees Structure  ................................ ................................ ................................ .51 
[IP_ADDRESS].  Internal Safety team  ................................ ................................ ................................ ....51 
[IP_ADDRESS].  Cardiac Event Adjudication Committee  ................................ ................................ .....51 
10.1.7.  Dissemination of Clinical Study Data  ................................ ................................ ........ 51 
10.1.8.  Data Quality Assurance  ................................ ................................ .............................. 52 
10.1.9.  Source Documents  ................................ ................................ ................................ ......52 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 6 10.1.10.  Study and Site Start and Closure  ................................ ................................ ................ 53 
10.1.11.  Publication Policy  ................................ ................................ ................................ .......53 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ .......55 
10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ........ 56 
10.3.1.  Definition of AE  ................................ ................................ ................................ ......... 56 
10.3.2.  Definition of SAE  ................................ ................................ ................................ .......57 
10.3.3.  Definition of MAAE  ................................ ................................ ................................ ...58 
10.3.4.  Definition of AESI  ................................ ................................ ................................ ......58 
10.3.5.  Recording and Follow -Up of AE and/or SAE  ................................ ............................ 58 
10.3.6.  Reporting of SAEs/AESI  ................................ ................................ ............................ 61 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ ...................... 63 
10.4.1.  Definitions  ................................ ................................ ................................ .................. 63 
10.4.2.  Contraception Guidance  ................................ ................................ ............................. 64 
10.5.  Appendix 5: Adverse Event of Special Interest  ................................ .......................... 66 
10.6.  Appendix 6: CDC Working Case Definitions of Pericarditis, Myocarditis, 
and Myopericarditis Occurring After Receipt of COVID -[ADDRESS_504087] OF TABLES  
Table  1: Schedule of Activities  ................................ ................................ ................................ .13 
Table  2: Objectives and Endpoints  ................................ ................................ ........................... 19 
Table  3: Study Interventions Administered  ................................ ................................ .............. 26 
Table  4: Study Arms and Dosing Regimens  ................................ ................................ ............. 27 
Table  5: Analysis Sets  ................................ ................................ ................................ ............... 46 
Table  6: Protocol -required Safety Laboratory Tests  ................................ ................................ .55 
Table  7: Adult and Adolescent Solicited Adverse Reactions and Grades  ................................ 59 
Table  8: Adverse Events of Special I nterest  ................................ ................................ ............. 66 
Table  9: Case Definitions of Probably and Confirmed Myocarditis, Pericarditis, and 
Myopericarditis  ................................ ................................ ................................ ........... [ADDRESS_504088] research organization  
CSR  clinical study report  
D day 
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
eDiary  electronic diary  
EKG  electrocardiogram  
EoS end-of-study  
FAS full analysis set  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GM geometric mean  
GMFR  geometric mean fold rise  
GMT  geometric mean titer  
HA hemagglutinin  
HAI hemagglutination inhibition  
HIV human immunodeficiency virus  
IA interim analysis  
IB Investigator’s Brochure  
ModernaTX, Inc.  
mRNA -CRID -[ADDRESS_504089] Term  Definition  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IM intramuscular(ly)  
IMP investigational medicinal product  
IRB institutional review board  
IST internal safety team  
IVRS  interactive voice  response system  
IWRS  interactive web response system  
LLOQ  lower limit of quantification  
LNP  lipid nanoparticle  
LTFU  lost to follow -up 
M month 
MAAE  medically attended adverse event  
MedDRA  Medical Dictionary for Regulatory Activities  
mRNA  messenger ribonucleic acid  
NH Northern Hemisphere  
NIMP  noninvestigational  medicinal product  
NP nasopharyngeal  
POCBP  person  of childbearing potential  
PONCBP  person  of non childbearing  potential  
PP per protocol  
RSV  respi[INVESTIGATOR_399940] -CoV -2 severe acute respi[INVESTIGATOR_6507] 2  
SC safety call  
SoA Schedule of Assessments  
ULOQ  upper limit of quantification  
USV  unscheduled visit  
UTR  untranslated region  
WHO  World Health Organization  
 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 10 1. PROTOCOL SUMMARY  
1.1. Protocol Synopsis  
Protocol Title:  
A Phase 2, randomized, active -controlled, observer -blind, dose -ranging study to evaluate the 
safety, reactogenicity , and immunogenicity of mRNA vaccine candidate variations in healthy 
adults 18  to 49 years of age . 
Brief  Title:  
Study to evaluate the safety, reactogenicity , and immunogenicity of mRNA vaccine candidate 
variations in healthy adults 18 to 49 years of age . 
Regulatory Agency Identifier Number:  
Registry  ID 
FDA  IND 028259  
Rationale : 
The aim of this Phase 2 study is to identify common or unique adaptive and innate immune 
signals or inflammat ory biomarkers  with predictive value for mRNA vaccine -induced 
immunogenicity and/or reactogenicity to support the Sponsor’s mRNA -based vaccine platform 
and mRNA -1010 vaccine development.  This study will be performed in an exploratory manner 
 
 
 
 
 
 
Objectives  and Endpoint s: 
Objectives  Endpoints  
Primary  
• To evaluate the safety and 
reactogenicity of mRNA -1010 vaccine 
candidate variations.  • Solicited local and systemic ARs through 7 days after 
study intervention.  
• Unsolicited AEs through 28 days after study 
intervention.  
• Medically attended AEs from Day 1 to Eo S. 
• AESIs from Day 1 to EoS.  
• SAEs from Day 1 to EoS.  
• AEs leading to study or treatment discontinuation from 
Day 1 to EoS . 
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 11 Objectives  Endpoints  
Secondary  
• To evaluate the humoral 
immunogenicity of mRNA -1010 
vaccine candidate variations at 
evaluable humoral immunogenicity 
timepoints.  • GMT at indicated timepoints as measured by [CONTACT_14294].  
• GMFR, comparing each timepoint with D1 (Baseline) as 
measured by [CONTACT_14294].  
• Percentage of participants with seroresponse a for 
mRNA -1010 at indicated timepoints, as measured by 
[CONTACT_14294].  
 
 
Abbreviations: AE =adverse event; AESI=adverse events of special interest; AR=adverse reaction; D=day; 
EoS=end-of-study; GMFR =geometric mean  fold rise; GMT =geometric mean titer; HAI =hemagglutination 
inhibition; LLOQ=lower limit of quantification; SAE =serious adverse event.  
a. Vaccine seroresponse is defined as an increase of antibody titers and concentrations from predose below the 
LLOQ to ≥4 × LLOQ, or at least a 4 -fold rise if predose is ≥LLOQ.  
Overall Design  Synopsis : 
This will be a randomized, observer -blind, Phase 2 study to evaluate the safety, reactogenicity 
and immunogenicity of mRNA -1010 vaccine candidate variations using a systems biology 
approach in healthy adults 18 to 49 years of age.  
Approximately 270 participant s will be randomly assigned in a ratio of 2:1:2:1:1:2  to one of 
6 study arms to receive one of the following treatments:  
• mRNA -1010  at 1 dose level  administered as a single dose . 
• mRNA -1010.4 at 1 of 2 dose levels  administered as a single dose . 
• mRNA -1010.[ADDRESS_504090] charter.  
An independent CEAC of medically qualified personnel, including cardiologists, will review all 
suspected cases of myocarditis and pericarditis to determine if they meet CDC criteria of 
“probable” or “confirmed” events which are reported in ongoing interventional clinical trials per 
the CEAC charter.  
Brief Summary : 
The study aims  to identify common or unique adaptive and innate immune signals  or 
inflammato ry biomarker s with predictive value for immunogenicity and/or reactogenicity  of 
mRNA -1010 , mRNA -1010.4 and mRNA -1010.6  in healthy adult participants 18 to 49 years of 
age. 
Study details include:  
• Study visits for all participants will consist of a Screening Visit (up to 28  days before 
the D1 visit), a Study Intervention Visit at D1, and Clinic Visits  
 
 
• All participants will be a sked to complete an eDiary for solicited ARs for 7  days (ie, 
the day of study intervention dosing and 6 subsequent days).  
• Frequent blood sample s will be collected  for the first 7  days to support the 
explora tory objective  of the study . 
• Collection of all AEs  will be through 28  days after study intervention dosing (ie, the 
day of study intervention dosing and 27 subsequent days). Collection of MAAEs, 
AESI, SAEs, and AEs leading to discontinuation from study participation will 
continue through /EoS.  
Number of Participants:  
Approximately  270 participants will be enrolled . 
Note : Enrolled  means participants’ or their legally acceptable representatives’, agreement to 
participate in a clinical study following completion of the informed consent process and 
screening . Potential participants who are screened for the purpose of determining eligibility for 
the study, but do not participate in the study, are not considered enrolled, unless otherwise 
specified by [CONTACT_760]. A participant will be considered enr olled if the informed consent is not 
withdrawn prior to participating in any study activity after screening.  
Study Arms and Duration : 
• The study will comprise 6 study arms.  
• The total duration of study participation is up to 7  month s from the Screening Visit . 
1.2. Schema  
Not Applicable .
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 13 1.3. Schedule of Activities  
The SoA is listed in Table  1. 
Table  1: Schedule of Activities  
Visit Number   1 2 3 4 5 6 7 8 9 10 USVa 
Type of Visit  C C C C C C C SC C SC SC C C 
Month Timepoint    
Study Vi sit Day  Screeningb 
Window 
Allowance (Days)  -28 NA NA 0 ±1 -1 to 
+3 -7 to 
+3 ±5 ±5 ±5 ±5 ±[ADDRESS_504091] 
Study 
Intervention   
ICF, 
demographics, 
concomitant 
medications, 
medical history  X X            
Inclusion/exclusion 
criteria  X X            
Physical 
examinationd X X            
Vital signse X X            
Pregnancy testingf X X            
Blood for humoral 
immunogenicityg  X    X X  X   X  
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 14 Visit Number   1 2 3 4 5 6 7 8 9 10 USVa 
Type of Visit  C C C C C C C SC C SC SC C C 
Month Timepoint    
Study Vi sit Day  Screeningb 
Window 
Allowance (Days)  -28 NA NA 0 ±1 -1 to 
+3 -7 to 
+3 ±5 ±5 ±5 ±5 ±[ADDRESS_504092] 
Study 
Intervention   
NP swab for virus 
detectionh  X           X 
Randomization   X            
Study intervention 
(including 30 -
minute postdosing 
observation period)   X            
eDiary activation 
for recording 
solicited ARs 
(7 days)i  X            
CCI
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 15 Visit Number   1 2 3 4 5 6 7 8 9 10 USVa 
Type of Visit  C C C C C C C SC C SC SC C C 
Month Timepoint    
Study Vi sit Day  Screeningb 
Window 
Allowance (Days)  -28 NA NA 0 ±1 -1 to 
+3 -7 to 
+3 ±5 ±5 ±5 ±5 ±[ADDRESS_504093] 
Study 
Intervention   
Review of eDiary 
ARsj      X        
Follow -up safety 
callsk        X  X X   
Unsolicited AEsl  X X X X X X       
SAEs  X X X X X X X X X X X X X 
AESIs, MAAEs, 
and AEs leading to 
withdrawal from 
the studym  X X X X X X X X X X X X 
Concomitant 
medications and 
nonstudy  
vaccinationsm  X X X X X X X X X X X X 
Abbreviations: AE =adverse event; AESI =adverse event of special interest; AR =adverse reaction; BMI=body mass index; C=clinic; COVID -19=coronavirus 
disease 2019 ; D=Day; EoS =end-of-study; e Diary=electronic diary; FDA =Food and Drug Administration; FSH =follicle -stimulating hormone; ICF =informed 
consent form; M =month; MAAE =medically attended AE; NA=not applicable; NP=nasopharyngeal; SAE =serious adverse event; SC =safety call; 
USV =unscheduled visit. 
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 16 Note:  In accordance with “FDA Guidance  on Conduct of Clinical Trials of Medical Products during COVID -19 Public Health Emergency” (DHHS 2020 ), 
Investigators may convert study site visits to telemedicine visits with the approval of the Sponsor.  
a. Participants may experience AEs that necessitate a USV. Additional examinations may be conducted at these visits as necessary to ensure the safety and 
well-being of participants during the study . 
b. The Screening Visit and Day [ADDRESS_504094] vaccine injection  on D1 . 
d. A full physical ex amination, including height , weight, and BMI will be performed at Screening. Symptom -directed physical examinations may be performed 
at other  timepoints at discretion of the Investigator. On each dosing day before injection, the arm receiving the injection  should be examined and the associated 
lymph nodes should be evaluated. Any clinically significant finding identified by a healthcare professional during study visits should be reported as an MAAE . 
e. Vital signs measurements: Systolic and diastolic blood pre ssures, pulse rate, respi[INVESTIGATOR_697], and body temperature. The preferred route of temperature 
assessment is oral. On the day of vaccination, vital signs will be collected once before vaccination and once at least [ADDRESS_504095] cannot be confirmed as negative (eg, an ambiguous result), a seru m pregnancy test is required. The participant’s FSH level may be 
measured at the Screening Visit, as necessary, and at the discretion of the Investigator , to confirm postmenopausal status . 
g. D1 (Baseline) b lood samples for  
 
h. An NP swab specimen for viral respi[INVESTIGATOR_399941] 1. At USV s participants  with 
symptoms of respi[INVESTIGATOR_399942]’s discretion  to include influenza, RSV and 
SARS -CoV -2, which may impact analyses  of reactogenicity  and immunogenicit y. 
i. eDiary entries will be recorded by [CONTACT_340142] [ADDRESS_504096] information relating to any MAAEs, AESIs, AEs leading to withdrawal  from the study , SAEs, 
information on concomitant medications associated with those events; receipt of any non study  vaccinations ; and receipt of any systemic steroids, 
immunosuppressive therap ies (drugs or biologics) , immunoglobulins , and/or blood products . 
l. All unsolicited AEs will be recorded starting the day of each study  intervention , and through 28  days following each study intervention . 
m. All concomitant medications will  be recorded through 28  days after vaccination. All concomitant medications relevant to or for the treatment of the SAE, 
AESI, MAAE, or AE leading to study withdrawal will be recorded from D1 through EoS. Any non study  vaccinations will be recorded from D1 through EoS.  
 
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 17 2. INTRODUCTION  
2.1. Study Rationale  
The aim of this Phase 2 study is to identify common or unique adaptive and innate immune  
signals  or inflammato ry biomarkers  with predictive value for mRNA vaccine -induced 
immunogenicity and/or reactogenicity to support the Sponsor’s mRNA -based vaccine platform 
and mRNA -1010 vaccine development.  
 
 
 
 
 
2.2. Background  
ModernaTX, Inc. (the Sponsor) has developed a proprietary vaccine platform based on mRNA 
delivered through LNPs . The platform is based on the principle and observations that cells in 
vivo can t ake up LNP -encapsulated mRNA, translate it, and then express protein antigen(s) on 
the cell surface or secrete the antigens. The intracellularly delivered mRNA does not enter the 
cellular nucleus or interact with the genome, is nonreplicating, and is expre ssed transiently. 
Strongly encouraged by [CONTACT_399957] -based SARS -CoV -2 vaccine 
(mRNA -1273; Spi[INVESTIGATOR_135893]®), the Sponsor is currently using the mRNA/LNP -based vaccine 
delivery platform to develop vaccines against multiple viruses, inclu ding influenza 
(mRNA -1010), RSV  (mRNA -1345), and cytomegalovirus ( mRNA -1647).  
mRNA -1010 is an LNP -encapsulated, mRNA -based, prophylactic vaccine containing 4 mRNAs 
in an equivalent mRNA mass ratio that encode membrane -bound HA of the 4 different influenza 
strains, recommended by [CONTACT_46324] 2022 -2023 NH cell or recombinant based vaccines.  The 
Sponsor has completed a Phase 1/2 study of mRNA -1010 ([STUDY_ID_REMOVED]) at dose levels up to 
 and is now conducting several Phase 3 studies at a  dose level  (NCT 05415462  and 
[STUDY_ID_REMOVED]) . 
This study will evaluate several v ersions of the Sponsor’s seasonal influenza mRNA vaccine 
candidate ( mRNA -1010) that are currently being evaluated in separate clinical Phase 1/2 
(mRNA -1083 -P101) and Phase 3 development studies ( mRNA -1010 -P303) for their ability to 
further optimize the immunogenicity and tolerability of the mRNA -1010 vaccine.   
 
 
 
Additional details  of mRNA -1010 are  provided in the IB.  
2.3. Benefit/Risk Assessment  
2.3.1.  Risk Assessment  
There have been very rare ( <1 in 10,000 recipi[INVESTIGATOR_840]) reports of myocarditis and pericarditis 
occurring after vaccination with COVID -[ADDRESS_504097] been reported in adolescents and young male s shortly  after the second or  
subsequent doses of the vaccine. These are typi[INVESTIGATOR_62707] , and individuals tend to recover 
within a short time following conservative  treatment (including rest, NSAIDs , and/or colchicine) . 
Healthcare professionals  and study participants should be al ert to the signs and symptoms of 
myocarditis and pericarditis (Gargano et al 2021 ). It is not known whether the risk of myocarditis 
or pericarditis is increased following additional doses of other non -COVID mRNA vaccines.  
Safety and reactogenicity data from multiple studies with mRNA -1010  ([STUDY_ID_REMOVED],  
[STUDY_ID_REMOVED] , and [STUDY_ID_REMOVED] ) have revealed no safety concerns  to date. Additional details 
are provided in the IB . 
2.3.2.  Benefit Assessment  
Participants will obtain information  about their general health status through the medical 
evaluations/assessments associated with this study ( eg, physical examination, vital signs 
measurement, and s ymptom -directed physical examination ). 
Participants will be contributing to the process of developi[INVESTIGATOR_007] a new potentially prophylactic 
measure for infection with influenza or other  pathogens . 
2.3.3.  Overall Benefit /Risk Conclusion  
Considering the safety data for mRNA -1010 to date, the Sponsor considers the potential benefits 
of participation to exceed the risks.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 19 3. OBJECTIVES  AND ENDPOINTS  
Table  2: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the safety and 
reactogenicity of mRNA -1010 vaccine 
candidate variations.  • Solicited local and systemic ARs through 7 day s after 
study intervention.  
• Unsolicited AEs through 28 days after study 
intervention.  
• Medically attended AEs from Day 1 to EoS.  
• AESIs from Day 1 to EoS.  
• SAEs from Day 1 to EoS.  
• AEs leading to study or treatment discontinuation from 
Day 1 to EoS . 
Secondary  
• To evaluate the humoral 
immunogenicity of mRNA -1010 
vaccine candidate variations at 
evaluable humoral immunogenicity 
timepoints.  • GMT at indicated timepoints as measured by [CONTACT_14295].  
• GMFR, comparing each timepoint with D1 (Baseline) as 
measured by [CONTACT_14294].  
• Percentage of participants with seroresponse a for 
mRNA -1010 at indicated timepoints, as measured by 
[CONTACT_14294].  
Abbreviations: AE =adverse event; AESI=adverse events of special interest; AR=adverse  reaction; D=day; 
EoS=end-of-study; GMFR =geometric mean  fold rise; GMT =geometric mean titer; HAI =hemagglutination 
inhibition; LLOQ =lower limit of quantification ; SAE =serious adverse event.  
a. Vaccine seroresponse is defined as an increase of antibody titers and concentrations from predose below the 
LLOQ to ≥4 × LLOQ, or at least a 4 -fold rise if predose is ≥LLOQ.  
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 20 4. STUDY DESIGN  
4.1. Overall Design  
This will be a randomized, observer -blind, Phase 2 stu dy to evaluate the safety, reactogenicity 
and immunogenicity of mRNA -1010 vaccine candidate variations using a systems biology 
approach in healthy adults 18 to 49 years of age.  
Three mRNA -1010 vaccine candidate v ersions  will be evaluated ( Table  3): 
• mRNA -1010 :  
 
 
 
• mRNA -1010.4 :  
 
• mRNA -1010.6:  
 
 
 
 
This study will  initially  enroll approximately 270 participants 18 to 49 years of age. Participants 
will be randomly assigned to study arms 1, 2, 3, 4, 5, and 6 in a ratio o f 2:1:2:1:1:2 to receive a 
single dose of 1 of the 3 mRNA -1010 vaccine candidate variations (ie, mRNA -1010, 
mRNA -1010.4, or mRNA -1010.6). Randomization will be stratified by [CONTACT_399958] a 2022 -2023 
NH influenza vaccine (Yes/No).  The different arms will include different dose levels for 
mRNA -1010.[ADDRESS_504098] of a Screening Visit (up to 28  days before the D1 
visit), a Study Intervention Visit at D1, and Clinic Visits  
 
 The duration of study participation for all participants is up to 7  month s 
from the Screening Visit. Refer  to the SoA ( Table  1), for more details.  
Safety Oversight  
Safety monitoring for this study will include the blinded study team members, including, at least, 
the Sponsor Medical Monitor, a CRO  Medical Monitor, a Clinical Safety Physician , and an 
unblinded IST. The unblinded IST will comprise  [ADDRESS_504099] charter.  
CCI
CCI
CCI
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 21 An independent CEAC of medically qualified personnel, including cardiologi sts, will review all 
suspected cases of myocarditis and pericarditis to determine if they meet CDC criteria of 
“probable” or “confirmed” events which are reported in ongoing interventional clinical trials per 
the CEAC charter (Gargano et al 2021 ). 
4.2. Scientific Rationale for Study Design  
The study is designed as a randomized, observer -blind dose -ranging study to evaluate the safety, 
reactogenicity , and immunogenicity of mRNA vaccine candidate variations in healthy adults 
18 to 49 year s of age . The randomized  and observer -blind design will ensure unbiased collection 
of safety and immunogenicity data.  
This study will evaluate several v ersions  of the Sponsor’s seasonal influenza mRNA vaccine 
candidate ( mRNA -1010).  
 
 
 
 
 
This study will be performed in an exploratory manner  
 
 
 
 
 
4.3. Justification for Dose  
Participants will receive either 1 dose  level  of mRNA -1010  1 of 2 dose levels of 
mRNA -1010.4 ); or 1 of 3 dose levels of mRNA -1010.6  
administered on Day  1 (refer to Table  3). 
The selected dose levels in this study are based on the observed reactogenicity and 
immunogenic ity profile s in clinical  Phase 1/[ADDRESS_504100] scheduled 
procedure as shown in the SoA ( Table  1) for th e last participant in the study.  
A participant is considered to have completed the study if he or she has completed all parts of the 
study, including the last visit or scheduled procedure as shown in the SoA ( Table  1). 
CCI
CCI
CCI
CCI
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 22 5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Adults 18 to 49 years of age at the time of consent ( Screening Visit) who, in the opi[INVESTIGATOR_18959], are in good health based on review of medical  history and physical 
examination performed at screening.  
Sex and Contraceptive/Barrier Requirements  
2. A participant  AFAB  is eligible to participate if not pregnant or breastfeeding, and  one of 
the following conditions applies:  
• Is a PONCBP as defined in Clinical Study Protocol, Appendix  4. 
OR 
• Is a POCBP and using a n acceptable  contraceptive method as described in 
Appendix  [ADDRESS_504101] 
3 months after the dose of study intervention. The Investigator should evaluate the 
potential for contraceptive method failure (eg,  noncompliance, recently initiated) in 
relationship to the dose of study intervention.  
A POCBP must have a negative highly sens itive pregnancy test (urine or serum as 
required by [CONTACT_427]) at the Screening Visit and again before the  dose of  
study intervention  if Day 1 is not on the same day as  the Screening Visit  (see 
Section  8.3.3 ). 
o If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. If the serum pregnancy result is positive , the 
participant must be exclude d from participation.  
The Investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a participant with an early 
undetected pregnancy.  
Informed Consent  
3. Capable of giving signed informed consent as described in Section  10.1.3 , which includes 
compliance with the requirements and restrictions listed in  the ICF and in this protocol . 
4. Participant has provided written informed consent for participation in this study, 
including all evaluations and procedures as specified in this protocol.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 23 5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
5. Participant has had close contact [CONTACT_46330] -confirmed influenza 
infection or with someone who has been treated with antiviral therapi[INVESTIGATOR_14268] (eg, 
Tamiflu®) within the past 5  days prior to D1. 
6. Participant has tested positive for influenza by [CONTACT_14306] -approved testing 
methods within 150  days prior to D1.  
7. Is acutely ill or febrile (temperature ≥38.0°C/100.4°F) within [ADDRESS_504102] participant safety, assessment of safety endpoints, assessment of 
immune response, or adherence to study procedures. Clinically unstable is defined as a 
diagnosis or condition requiring significant changes in management or medication within 
the 60  days prior to Screening and includes ongoing workup of an undiagnosed illness 
that could lead to a new diagnosis or condition.  
9. Asymptomatic conditions and conditions with no evidence of end -organ involvement (eg, 
mild hypertension, dyslipi[INVESTIGATOR_035]) are not ex clusionary, provided that they are being 
appropriately managed and are clinically stable (ie, unlikely to result in symptomatic 
illness within the time -course of this study). Illnesses or conditions may be exclusionary, 
even if otherwise stable, because of  immunosuppressive therapi[INVESTIGATOR_014] (drugs or biologics)  
used to treat them, at the discretion of the Investigator.  
• Participants who have undergone surgical procedures within 7  days prior to Day 1 or 
are scheduled to undergo a surgical procedure within 28  days after study injection are 
also excluded. However, minor  surgical procedures under local anesthesia 
(eg, excision of skin lesion) or diagnostic procedures (eg, colonoscopy) are allowed.  
10. Any medical, psychiatric, or occupational condition, including reported h istory of 
substance abuse, that may pose additional risk as a result of participation, or that 
could interfere with safety assessments or interpretation of results according to the 
Investigator’s judgment.  
11. Has a current or previous diagnosis of congenital or acquired immunodeficiency, to 
include HIV, immunosuppressive condition or immune -mediated (autoimmune) 
disease, asplenia, or recurrent severe infections , that requires treatment with systemic 
immunosuppressive drugs or biologics. Participants who use to pi[INVESTIGATOR_399943] (eg, topi[INVESTIGATOR_73199]) may be eligible for 
participation at the discretion of the Investigator.  
12. History of anaphylaxis, urticaria, or other significant AR requiring medical 
intervention a fter receipt of mRNA vaccines or any components of the mRNA -[ADDRESS_504103] local solicited AR assessments (eg, tattoos, 
psoriasis patches affecting skin over the deltoid areas).  
16. Diagnosis of malignancy within the previous 2 years (excluding nonmelanoma skin 
cancer).  
17. History of Guillain -Barre syndrome.  
Prior/Concomitant Therapy  
18. Has received systemic immunosuppressive therapy (drugs or biologics)  for more than 
14 days within 180 days prior to Screening (for corticosteroids ≥10 mg/day of 
prednisone equivalent) or is anticipating  the need for  systemic  immunosuppressive 
treatment at any time during participation in the study. Inhaled, nasal, and topi[INVESTIGATOR_56785].  Intra -articular and epi[INVESTIGATOR_399944] 28  days before and/or after study int ervention  dosing . 
19. Has received or plans to receive any licensed/authorized vaccine (to include 
SARS -CoV -2 vaccine) ≤28 days prior to or within 28 days after study intervention.  
20. Has received a licensed seasonal influenza vaccine within 5  month s (150  days) prior 
to D1 . 
21. Has participated in any investigational seasonal influenza vaccine study within 
[ADDRESS_504104] recent 
influenza season ( in the prior 12 month s). 
23. Has been treated with antiviral therapi[INVESTIGATOR_14268] (eg , Tamiflu®) within [ADDRESS_504105] immune 
responses (eg, infliximab) within 90  days prior to the Screening Visit/ Day 1, or plan 
to receive them, are also excluded.  
Prior/Concurrent Clinical Study Experience  
25. Has donated ≥450 mL of blood products within 28  days prior to the Screening Visit 
or plans to donate blood products during the study.  
26. Participated in an interventional clinical study within 28  days prior to the Screening 
Visit based on the medical history interview or pla ns to participate in an 
interventional clinical trial of an investigational vaccine or drug while participating in 
this study.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 25 Other Exclusion Criteria  
27. Is working or has worked as study personnel or i s an immediate family member or 
household member of stud y personnel, study site staff, or Sponsor personnel.  
5.3. Screen Failures  
A screen failure occurs when a participant who has consent ed to participate in the clinical study 
is not subsequently assigned to study intervention . A minimal set of screen failure infor mation is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demography, screen failure details, eligibilit y criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened  once if they will be eligible upon rescreening . 
5.4. Criteria for Temporarily Delaying Administration of Study 
Intervention  
Body  temperature (oral temperature preferred) must be measured on dosing visits before vaccine 
administration. The following events constitute criteria for delay of injection, and if any of these 
events occur at the time scheduled for dosing, the participant m ay receive the study intervention 
at a later date , or the participant may be discontinued from dosing at the discretion of the 
Investigator ( Section  7.1): 
• Acute moderate or severe infection with or without fever at the time of dosing . 
• Fever, defined as body temperature ≥38.0°C/ ≥100.4°F at the time of dosing . 
Participants with a minor illness without fever, as assessed by [CONTACT_737], can be 
vacci nated.  
Participants with a fever of ≥38.0°C /≥100.4°F will be contact[CONTACT_340101] -evaluated for eligibility. If the Investigator determines that the 
participant’s health on the day of dosing temporarily precl udes injection, the visit should be 
rescheduled within the allowed interval for that visit.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 26 6. STUDY INTERVENTION S AND CONCOMITANT THERAPY  
Study interventions are all prespecified investigational and NIMP s, medical devices , and other 
interventions (eg, surgical and behavioral) intended to be administered to the study participants 
during the study conduct.  
6.1. Study Interventions Administered  
The study interventions administered are listed in Table  3. 
Table  3: Study Interventions Administered  
Intervention 
Label  mRNA -1010  mRNA -1010.4  mRNA -1010.6  
Intervention 
Descrip tion LNP  dispersion encoding 4 seasonal influenza vaccine antigens, HAs, from the 
influenza strains recommended by [CONTACT_46324] 2022 -2023 NH  cell- or 
recombinant -based influenza vaccines.  
All mRNAs are formulated in LNPs composed of 4 lipi[INVESTIGATOR_56783]  a sterile 
liquid for injection, white  to off white dispersion in appearance, in Tris buffer with 
sucrose, and sodium acetate at pH 7.5.  
Type  Vaccine  
Appearance  White to off -white dispersion for injection  
Dosage 
Strengths   
Single Dose   
 
Single Dose   
 
 
Single Dose  
Route of 
Administration  IM Injection  
Use Experimental  
IMP and 
NIMP/AxMP  IMP 
Packaging and 
Labeling  All study interventions  will be prepared, packaged, and labeled in accordance with 
the standard operating procedures of ModernaTX, Inc. or those of its designee, CFR 
Title 21, GMP guidelines, ICH and GCP guidelines, guidelines for Quality System 
Regulations, and applicable regul ations . 
Abbreviations: AxMP =auxiliary medicinal products ; CFR =code of federal regulation; GCP =good clinical practice: 
GMP =good manufacturing practice; HA=hemaggluti nin; ICH=International Council for Harmonisation; 
IM=intramuscular; IMP =investigational medicinal product; LNP=lipid nanoparticles; NH=Northern Hemisphere ; 
NIMP =noninvestigational  medicinal product.  
Study Arms and Dosing Regimens  
The study arms and dosing regimens are listed in Table  4. 
CCI
CCI
CCI
CCI
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 27 Table  4: Study Arms and Dosing Regimens  
Study 
Arm  Group Name  [CONTACT_399979] 
(Total)  N 
(Total)  Dose 
Schedule  
1 mRNA -1010 
(Single  dose)  
Influenza HA, quadrivalent for N H 60 D1 
2 mRNA -1010.4 
(Single  dose)  30 D1 
3 mRNA -1010.4 
(Single  dose)  60 D1 
4 mRNA -1010.6 
(Single  dose)  30 D1 
5 mRNA -1010.6 
(Single  dose)  30 D1 
6 mRNA -1010.6  
(Single  dose)  60 D1 
Abbreviations: D=day; HA= hemagglutinin; mRNA =messenger ribonucleic acid; N =number ; NH =Northern 
Hemisphere . 
6.2. Preparation , Handling , Storage , and Accountability  
1. The Investigator or designee must confirm appropriate conditions (eg, temperature)  
have been maintained during transit for all study intervention received , and any 
discrepancies are reported and resolved before use of the study intervention.  
2. Only participants enrolled in the study may receive study intervention , and only 
authorized site  staff may supply , prepare,  or administer study intervention.  
Note: Enrolled  means participants’, or their legally acceptable representatives’, 
agreement to participate in a clinical study following completion of the informed 
consent process and screening.  Potential participants who are screened for the 
purpose of determining eligibility for the study, but do not participate in the study, are 
not considered enrolled, unless otherwise specified by [CONTACT_760]. A participant will 
be considered enrolled if th e informed consent is not withdrawn prior to participating 
in any study activity after screening.  
3. All study intervention s must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storag e 
conditions with access limited to the Investigator and authorized site staff.  
4. The Investigator , institution, the head of the medical institution (where applicable), or 
authorized site staff is responsible for study intervention accountability, 
reconcilia tion, and record maintenance (ie, receipt, reconciliation, and final 
disposition records).  
5. Further guidance and information for the final disposition of unused study 
interventions are provided in the pharmacy manual . 
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 28 6.3. Assignment to Study Intervention  
All pa rticipants will be centrally assigned to randomized study intervention using an 
IVRS/IWRS. Before the study is initiated, the telephone number and call -in directions for the 
IVRS and/or the log -in information and directions for the IWRS will be provided to  each site.  
Study intervention will be dispensed as summarized in the SoA ( Table  1). 
Returned study intervention should not be redispensed to the part icipants.  
6.4. Blinding  
Refer to  Section  9.[ADDRESS_504106] of the study will 
remain blinded to individual treatment assignment until planned study unblinding  or EoS. 
The IVRS/IWRS will be programmed with blind -breaking instructions. In case of an emergency, 
the Investigator has the sole responsibilit y for determining if unblinding of a participants’ 
intervention assignment is warranted. Participant safety must always be the first consideration in 
making such a determination. If the Investigator decides that unblinding is warranted, the 
Investigator ma y, at the Investigator’s discretion, contact [CONTACT_399959] a participant’s intervention assignment unless this could delay emergency 
treatment for the participant. If a participant’s intervention assignment is unb linded, the Sponsor  
must be notified within [ADDRESS_504107] 
be recorded.  
Sponsor safety staff may unblind the intervention assignment for any participant with an SAE. If 
the SAE requires that an expe dited regulatory report be sent to one or more regulatory agencies, 
a copy of the report identifying the participant’s intervention assignment may be sent to 
Investigators in accordance with local regulations and/or Sponsor policy.  
6.5. Study Intervention Compl iance  
The study intervention will be administered at the study site under direct observation of 
medically qualified study staff, and study intervention administration will be appropriately 
recorded ( date and time) in the eCRF. Qualified  staff will confirm that the participant has 
received the entire dose of the study intervention. If a participant does not receive the study 
intervention , the reason for the missed dose will be recorded. Data will be reconciled with site 
accountability rec ords to assess compliance.  
The study site staff are responsible for ensuring that participants comply with the allowed study 
visit windows. If a participant misses a visit, every effort should be made to contact [CONTACT_14311] a visit within the defined visit window specified in the SoA (Table  1). 
If a participant does not complete a visit within the time window, that visit will be classif ied as a 
missed visit , and the participant will continue with subsequent scheduled study visits. All safety 
requirements of the missed visit will be captured and included in the subsequent visit . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 29 6.6. Dose Modification  
No dose modifications are allowed.  
6.7. Continu ed Access to Study Intervention after End -of-Study  
There will be no access to study intervention after EoS. 
6.8. Treatment of Overdose  
Because the study intervention is to be administered by a healthcare provider, it is unlikely that 
an overdose will occur.  
In the event of an overdose, the Investigator should:  
• Evaluate the participant to determine, in consultation with the Medical Monitor , if 
possible, whether study intervention should be interrupted or whether the dose should 
be reduced.  
• Closely monitor the participant for any AE/SAE and laboratory abnormalities until 
the last safety follow -up visit.  
• Report any signs or symptoms associated with the overdose as an AE and record 
details in the relevant AE/SAE sections in the eCRF.  
• Document t he quantity of the excess dose in the eCRF.  
Dose deviations will be tracked as protocol deviations.  
6.9. Prior and Concomitant Therapy  
Prior Medications and Therapi[INVESTIGATOR_399945] : 
• All prior medicati ons (including any prescription or over -the-counter medications, 
vaccines, or blood products) taken by [CONTACT_14312] 28  days before 
providing informed consent . 
• Any licensed  seasonal influenza vaccine administered  in the prior 12  month s. 
• Any licensed /authorized or  investigational COVID -19 vaccine  administered  at any 
time before study intervention  administration . 
• Any investigational influenza or RSV vaccine  administered at any time before study 
intervention administration . 
6.9.1.  Concomitant Medicatio ns and Therapi[INVESTIGATOR_399946] (including SCs), study site staff must question the participant regarding any 
medications taken and non study  vaccinations received by [CONTACT_399960] n for use, dates of administration 
including start and end dates and dosage information including dose and frequency : 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 30 • All concomitant medications administered through 28  days (the day of study 
vaccination and the subsequent 27  days) after study vaccine adm inistration. 
Antipyretics and analgesics taken prophylactically (ie, taken in the absence of any 
symptoms in anticipation of an injection reaction) will be recorded as such.  
• All non study  vaccinations administered from Screening through  EoS. 
• Systemic steroids, immunosuppressive therapy (drugs or biologics ), 
immunoglobulins, and/or blood products administered from Screening through EoS.  
• Any concomitant medications or vaccines relevant to or for the treatment of an AESI , 
MAAE,  or AE leading to s tudy or treatment discontinuation will be recorded from the 
first dose at Day 1 through the EoS.  
• Any concomitant medications or vaccines relevant to or for the treatment of a SAE 
will be recorded from the signing of ICF through the EoS.  
The Medical Monitor  should be contact[CONTACT_63193].  
The participant will be asked in the eDiary if they have taken any antipyretic or analgesic 
medication to treat or prevent fever or pain within 7  days after the study v accination, including 
the day s of injection. Reported antipyretic or analgesic medications should be recorded in the 
source document by [CONTACT_399961] ( eg, telephone call s). 
Concomitant medications (including vaccinations) will be coded using WHODrug Globa l. 
It is the Investigator’s responsibility to ensure that details regarding the concomitant medications 
are adequately recorded in the eCRF . 
All medication and interventi ons necessary for the appropriate care of the study participant 
should be administered and appropriately documented along with the AE for which the treatment 
was initiated.  
6.9.2.  Conco mitant Medications and Vaccines that May Lead to the  Elimination of a 
Participant from Per Protocol Analyses 
The use of the following concomitant medications and/or vaccines will not require withdrawal of 
the participant from the study but may determine a participant’s evaluability in the PP analysis. 
Analysis sets are desc ribed in  Section  9.4. 
• Any investigational or nonregistered product (drug or vaccine) other than the study 
vaccine used during the study period.  
• Systemic immunosuppressive therapy (drugs or biologics ) administered  chronically 
(ie, more than 14  days in total) during the study period. For glucocorticosteroids, this 
will mean that prednisone ≥10 mg/day or the equivalent is not permitted. Inhaled, 
nasal, and topi[INVESTIGATOR_14271].  Intra -articular and epi[INVESTIGATOR_399947] 28  days after study intervention dosing.  
• An authorized or licensed vaccine, including SARS -CoV -2 vaccine, administered 
28 days before and after study intervention.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 31 • Long -acting immunosuppressive therapy  (drugs or biologics ) administe red at any 
time during the study period ( eg, infliximab).  
• Immunoglobulins and/or any blood products administered during the study period.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 32 7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
Discontinuation of specific sites or of the study as a whole are detailed in Section 10.1.10 . 
7.1. Discontinuation of Study Intervention  
Not applicable . 
7.2. Participant Disc ontinuation/Withdrawal from the Study  
• A participant may withdraw from the study at any time at the participant’s  own 
request for any reason (or without providing any reason).  
• A participant may be withdrawn at any time at the discretion of the Investigator for 
safety, behavioral, or compliance  reasons.  
• At the time of discontinuing from the study, if possible, an early discontinuation visit 
should be conducted, as shown in the S oA (Table  1). See the SoA ( Table  1) for data 
to be collected at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed . 
• A participant who withdraws from the study will not be replaced.  
• If the participant withdraws consent for disclosure of future information, the Sponsor  
may retain and continue to use any data collected before such a withdrawal of 
consent.  
• If a participant withdraws from the study, the participant  may request d estruction of 
any samples taken and not tested, and the Investigator must document this in the site 
study records.  
• The Sponsor  will continue to retain and use all research results that have already been 
collected for the study evaluation. All biological sa mples that have already been 
collected may be retained and analyzed at a later date (or as permitted by [CONTACT_13125]) . 
From an analysis perspective, a “withdrawal” from the study refers to a situation wherein a 
participant does not return for the fina l visit foreseen in the protocol. All data collected until the 
date of withdrawal or last contact [CONTACT_14314]. A participant is 
considered a “withdrawal” from the study when no study procedure has occurred, no follow -up 
has been performed, and no further information has been collected for that participant from the 
date of withdrawal or last contact.  
Information relative to the withdrawal will be documented in the EDC. The Investigator will 
document whether the decision t o withdraw a participant from the study was made by a 
participant or by [CONTACT_399962]:  
• AE. 
• SAR/ reactogen icity. 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 33 • Death . 
• LTFU . 
• Noncompliance with study  procedures . 
• Physician decision . 
• Pregnancy . 
• Protocol deviation . 
• Screen failure . 
• Study terminated by [CONTACT_2728] . 
• Withdrawal by [CONTACT_3445] . 
• Other . 
Participants who are withdrawn from the study because of an AE (including SAE, MAAE and 
AESI)  or SAR/Reactoge nicity  event  must be clearl y distinguished from participants who are 
withdrawn for other reasons. Investigators will follow -up with participants who are withdrawn 
from the study because of an AE /SAE/AESI/MAAE  or SAR /reactogenicity event until resolution 
of the event.  
7.3. Lost to Follow -up 
If a participant does not complete a visit within the time window specified in the SoA ( Table  1), 
every effort should still be made to complete the assessments for that visit (even though outside 
of the defined visit window); the participant will continue with subsequent scheduled study  visits 
per their original schedule ( ie, relative to their Day 1 visit). If a participant still does not 
complete the visit after all these efforts, the visit will be classified as missed and all safety 
requirements of the missed visit will be captured and  included in the subsequent visit.  
A participant  will be considered LTFU  if the participant  repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant fails to retur n to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_14315], counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the  participant wishes to and/or should 
continue in the study.  
• Before a participant is deemed LTFU , the Investigator or designee must make every 
effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls, and if 
necessary, a certified le tter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_21457]’s medical record.  
• Should the participant continue to be unreachable, the participant will be considered 
to hav e withdrawn from the study.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 34 • A participant should be not considered LTFU  until due diligence has been completed.  
7.4. Pause Rules  
Not applicable . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 35 8. STUDY ASSESSMENTS AND PROCEDURES  
• Before performing any study procedures, all potential participants will sign an ICF  
(Section  10.1.3 ). 
• Study procedures and their timing are summarized in the SoA  (Table  1). Protocol  
waiv ers or exemptions are not allowed.  
• Adherence to the study design requirements, including those specified in the SoA  
(Table  1), is essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count)  and obtained before signing of the ICF may be utilized for screening or 
Baseline purposes provided the procedures met the protocol -specified criteria and 
were performed within the timeframe defined in the SoA  (Table  1). 
• In the event of a significant study -continuity issue (eg, caused by a pandemic), 
alternate strategies for participant visits, assessments, medication distribution and 
monitoring may be implemented by [CONTACT_14317] , as per local 
health aut hority/ethics requirements.  
• Study results  that could unblind the study will not be reported to investigative sites or 
other blinded personnel until the study has been unblinded.  
• The maximum amount of blood collected from each participant over the duration of 
the study, including any extra  assessments that may be required, will not exceed 
blood limits specified by [CONTACT_56819].  
• Repeat or unscheduled samples may be taken for sa fety reasons or for technical issues 
with the samples. Further details are provided in both the ICF and Laboratory 
Reference Manual.  
• If a visit cannot be scheduled within the indicated allowable window and /or the 
participant misses the visit , this is consi dered a protocol deviation. However, the visit 
should still be completed , if possible, to coll ect study data . Subsequent visits should 
be scheduled at the originally  planned number of days after D1 defined  in the SoA 
(Table  1). 
8.1. Demography  
Demographic information relating to the participant’s sex, age, and race will be recorded at 
Screening in the EDC.  
Medical history of each participant will be collected and recorded in the EDC. Significant 
findings that were present prior to the sign ing of the informed consent will also be included in 
the EDC.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 36 8.2. Immunogenicity Assessments  
Planned timepoints for all humor al and cellular immunogenicity  assessments are provided in the 
SoA (Table  1). The following analytes will be measured as appropriate:  
• Vaccine -specific humoral immune responses, including serum antibody levels as 
measured by [CONTACT_399963].  
 
 
•  
 
 
 
8.3. Safety Assessments  
Safety assessments will include monitoring and recording of the following for each participant 
(see the SoA [Table  1] for details):  
• Solicited local and systemic ARs that occur during the 7  days following vaccine 
administration (ie, the day of study injection and 6 subsequent days). Solicited ARs 
will be rec orded daily using eDiaries.  
• Unsolicited AEs observed or reported during the 28  days following each vaccine 
administration (ie, the day of study injection and 27 subsequent days).  Unsolicited 
AEs are AEs that are not included in the protocol -defined  solicit ed ARs . 
• AESIs, MAAEs, and AEs leading to discontinuation  from study participation from 
D1 (post study  intervention dosing)  through EoS  or discontinuation from the study . 
• SAEs from the signing of ICF through EoS or discontinuation from the study . 
• Vital sign measurements before and after study injection.  
• Physical examination findings.  
• Occurrence s of pregnanc y in participants will be collected after the start of study 
intervention and until the end of their participation in the study. All pregnancies must 
be followed to end of pregnancy . Pregnancy details and outcome data are to  be 
collected beyond EoS, when re quired  (ie, for pregnancies continuing beyond the EoS 
visit) . 
• Concomitant medications and nonstudy  vaccinations.  
8.3.1.  Physical Examinations  
• Physical examination including height, weight, and BMI will be performed at the 
timepoints indicated in the SoA ( Table  1). 
• A full examination will include assessment of skin, head, ears, eyes, nose, throat, 
neck, thyroid, lungs, heart, cardiovascular system, abdomen, lymp h nodes, and 
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 37 musculoskeletal system and extremities. Height and weight will also be measured and 
recorded as outlined in the SoA ( Table  1). 
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
• On the day of study intervention administration, before administration, the arm 
receiving the injection  should be examined , and the associated lymph node(s) should 
be evaluated.  
8.3.2.  Vital Signs  
• Vital signs will be measured at the timepoints indicated in the SoA ( Table  1). 
• Vital  sign measurements include systolic and diastolic blood pressure, pulse rate, 
respi[INVESTIGATOR_697], and body temperature (oral being the preferred route).  
• The participant will be seated for at least 5 minutes before all measurements are 
taken.  
• On study interve ntion day, vital sign measurements will be collected once before 
study vaccine injection and at least 30 minutes after study vaccine injection (before 
participants are discharged from the study site). If vital signs are clinically 
concerning, participant s hould not be dosed. When applicable, vital sign 
measurements should be performed before blood collection.  
• Participants must not eat or drink anything hot or cold within 10 minutes before oral 
temperature is taken.  
• Participants who are febrile (fever is def ined as a body temperature ≥38.0°C/100.4°F) 
before injection on dosing day must be rescheduled . Criteria for delay of study 
vaccine are provided in Section  5.4. Participants who are a febrile with minor illnesses 
may be injected at the discretion of the Investigator. If fever is clinically concerning, 
participant should not be dosed.  
• Abnormal vital sign measurements should be assessed by [CONTACT_399964]. The 
Investigator will continue to monitor the participant with additional assessments until 
the vital sign value has reached the reference range, returns to the vital sign value at 
Baseline, is considered stable, or until the Investigator determines that follow -up is no 
longer medically necessary.  
8.3.3.  Pregnancy Testing  
• Refer to Section 5.1 for pregnancy testing entry criteria.  
• Pregnancy testing (urine or serum as required by [CONTACT_427]) should be 
conducted for all POCBP at the Screening Visit and before study intervention  dosing 
on Day 1 , if Day 1 is not at the same day as the Screening Visit  (Table  1). 
• The FSH level may be measured at the Screening Visit as necessary, and at the 
discretion of the Investigator, to confirm postmenopausal status ( Table  1). 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 38 • Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_399965] b y local regulation, to establish the absence 
of pregnancy at any time during the participant’s participation in the study.  
8.3.4.  Assessments for Respi[INVESTIGATOR_399948](s) for viral respi[INVESTIGATOR_399949] 1. At USV s participants with symptoms of respi[INVESTIGATOR_399950]’s discretion, to include influenza, 
RSV and SARS -CoV -2, which may impact analyses of reactogen icity and immunogenicity.  
8.3.5.  Safety Calls  
An SC is a telephone call made to the participant by [CONTACT_1146]. This call will follow a 
script, which will facilitate the collection of relevant safety information. SCs will follow a 
schedule for each par ticipant, as shown in the SoA ( Table  1). The participant will be interviewed 
according to the script about occurrence of MAAEs, SAEs, AESIs, AEs leadi ng to withdrawal 
from the study, and concomitant medications associated with those events; receipt of any 
nonstudy  vaccinations, and receipt of any systemic steroids, immunosuppressive therapy (drugs 
or biologics ), immunoglobulins , and/or blood products . All safety information collected from the 
telephone call must be documented in the source documents as described by [CONTACT_399966]. An unscheduled follow -up SC may be 
triggered if an eDiary reco rd results in identification of a relevant safety event. A n SC may 
trigger a USV . 
8.3.6.  Use of Electronic Diaries  
At the time of consent, the participants must confirm they will be willing to complete an eDiary 
(for 7 -day reactogenicity). The local and systemic ARs that will be solicited by [CONTACT_46348]  7. 
Solicited local and systemic reactogenicity ARs will be collected on the day of each  study 
intervention and during the 7  days after study intervention (ie, the day of dosing and 
6 subsequent days). Details on the recording of local and systemic ARs are included in 
Section  8.4.[ADDRESS_504108] data into the eDiary starting approximately 
30 minutes after dosing under supervision of the site staff to ensure successful entry of 
assessments. The 30-minute observation period is an opportunity for site staff to train the 
participant on eDiary completion requirements. The site staff will perform any retraining as 
necessary.  
At each dosing visit, participants will be instructed or reminded on thermometer usage to 
measure b ody temperature, ruler usage to measure injection site erythema (redness) and 
swelling/induration (hardness), and self -assessment for localized axillary (underarm) swelling or 
tenderness ipsilateral (on the same) side as the injection arm during the 7  days after study 
intervention. Daily oral temperature measurement should be performed at approximately the 
same time each day using the thermometer provided by [CONTACT_7893].  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 39 The participant will be trained on how to complete the eDiary questions according to  the SoA 
(Table  1) and also reminded to call the site immediately if they experience any new signs or 
symptoms.  
If a participant does not respond to the eDiary questions according to the SoA, site staff will 
follow -up with the participant.  
8.4. Adverse Events , Serious Adverse Events , and Other Safety 
Reporting  
The definitions of AEs and SAEs can be found in Section  10.3. 
The definitions of unsolicited and solicited AEs can be found in Section 10.3. 
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE. The Investigator and any qualified 
designees shall be responsible for following up all AEs or SAEs or that caused the participant to 
discontinue the study intervention or study (see Section  7). This in cludes events reported by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant’s legally 
authorized representative).  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for complet ing and transmitting SAE reports are provided in Section 10.3. 
8.4.1.  Time Period and Frequency for Collecting AE and SAE Information  
All SAEs will be collected from the signing of ICF until the last day of study participation at the 
timepoints specified in the SoA ( Table  1). 
All, AESIs, MAAEs , and AEs leading to withd rawal from the study will be collected from the 
start of study intervention until the last day of study participation at the timepoints specified in 
the SoA ( Table  1). 
All other (unsolicited) AEs will be collected from the time of the administration of study 
vaccination through 28  days (the day of study vaccination and the subsequent 27  days) (see the 
SoA [Table  1]). 
Solicited ARs will be collected during the solicited period, for 7  days (the day of study 
vaccination and the subsequent 6  days). 
Non-serious m edical occurrences that begin before the star t of study intervention but after 
obtaining informed consent will be recorded as medical history/current medical conditions, not 
as AEs; however, if the condition worsens at any time during the study, it will be recorded and 
reported as an AE.  
All SAEs will be recorded and reported to the Sponsor or designee immediately and under no 
circumstance should this exceed [ADDRESS_504109] pursue and obtain 
information adeq uate to determine the outcome of the AE and to assess whether the AE meets 
the criteria for classification as an SAE, which requires immediate notification to the Sponsor or 
its designated representative.  
Care will be taken not to introduce bias when detec ting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences.  
8.4.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow eac h 
participant at subsequent visits/contacts. All SAEs and AESIs (as defined in Section  10.3.2  and 
Section  10.3.4 , respectively ) will be followed until resolution, stabilization, the event is 
otherwise explained, or the participant is LTFU  (as defined in Section  7.3), even if the event 
continues beyond the  participant’s EoS visit . Further information on follow -up procedures is 
provided in Section  10.3. 
8.4.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_399967] e 
safety of a study intervention under clinical investigation are met.  
• The Sponsor  has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor  will comply with country -specific regulatory requirements 
relating to  safety reporting to the regulatory authority, IRBs/IECs , and Investigators . 
• An Investigator who receives an Investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from the Sponsor  will 
review and  then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.  
• For expedited reporting purposes, the expectedness of SAEs will be assessed against 
the investigational treatment regimen the participant  is receiv ing at the time of the 
event. A E terms not listed as expected events in the IB for investigational product  
will be considered unexpected . 
• Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local 
regulatory requirements and Sponsor  policy and forwarded to Investigators as 
necessary.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 41 8.4.5.  Pregnancy  
• The effects of the study intervention on the unborn child and/or newborn baby [CONTACT_399968]. Therefore, is important that study participants are not pregnant and do not 
become pregnant during the study.  
• Pregnancy testing is scheduled  to occur at the Screening Visit and Day 1, if Day  1 is 
not at the same day as the Screening Visit  (Table  1). Participants who have a positive 
pregnancy test at the Screening Visit must not be enrolled  and participants who have 
a positive pregnancy test at Day [ADDRESS_504110] not receive the study intervention.  Additional 
pregnancy testing may also be performed at any time du ring the study if required by 
[CONTACT_35512], or at the discretion of the Investigator . 
• Details of all pregnancies in participants will be collected after the start of study 
intervention and until the end of their participa tion in the study . 
• If a pregnancy is reported, the Investigator will record pregnancy information on the 
appropriate form and submit it to  the Sponsor  within 24 hours  of learning of the 
participant  pregnancy . 
• Participants who have a positive pregnancy test after receiving s tudy intervention 
should remain in the study and be followed -up for safety.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE  (refer to Section  10.3). 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs  and will be reported 
as such  (refer to Section  10.3). 
• The participant  will be followed to determine the outcome of the pregnancy. General 
pregnancy and outcome  data may be collected beyond EoS (ie, for pregnancies 
continuing beyond EoS visit).  
8.4.6.  Solicited Adverse Reactions  
Solicited ARs are a subset of AEs consisting of selected signs and symptoms that participants are 
asked to record/report. In this study, the so licited ARs are reactogenicity events. The term 
“reactogenicity” refers to the occurrence of transient adverse effects associated with vaccine 
administration. The eDiary will solicit daily participant reporting of ARs using a structured 
checklist. Particip ants will record such occurrences in the eDiary on the day of each study 
vaccine injection and 6 subsequent days.  
Severity grading of reactogenicity will occur automatically based on participant entry into the 
eDiary according to the grading scales present ed in Appendix  3 (Section  10.3.5 ), which are 
modified from the Toxicity Grading Scales for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventative Vaccine Clinical Trials ( DHHS 2007 ). All solicited ARs (local and 
systemic) will be considered causally related to dosing.  
ModernaTX, Inc.  
mRNA -CRID -[ADDRESS_504111] be entered into the participant’s 
source document and must also be recorded by [CONTACT_399969] : 
• Solicited local or systemic ARs that were not recorded in the eDiary but reported to 
the study site/Investigator and is Grade 1 or greater . 
• Solicited local or systemic AR that results in a visit to a healthcare practitioner 
including USV s at the study site  (MAAE) . 
• Solicited local or systemic AR leading to the participant withdrawing from the study 
or the participant being withdrawn from the st udy by [CONTACT_737] (AE leading to 
discontinuation) . 
• Solicited local or systemic AR lasting beyond [ADDRESS_504112] injection . 
• Solicited local or systemic AR that leads to participant discontinuation from study 
intervention . 
• Solicited local or systemic AR th at otherwise meets the definition of an SAE 
(Section  10.3.2 ). 
If a participant reports a solicited AR with onset during the solicited period, but t hey did not 
record the event in the eDiary, then the event should be recorded by [CONTACT_399970].  
If the event starts during the solicited period, but continues beyond 7  days after dosing, the 
participants should no tify the site to provide an end date and close out the event in the EDC 
where reactogenicity is collected.  
If the participant reported an event that started after the solicited period (ie, beyond 7  days after 
dosing), it should be recorded as an unsolicite d AE in the EDC. Causality for these events will be 
determined per assessment by [CONTACT_737].  
8.4.7.  Medically Attended Adverse Events  
A MAAE is an AE that leads to a n unplann ed visit to a healthcare practitioner. This would 
include visits to a study site f or unscheduled assessments (eg, rash assessment, abnormal 
laboratory follow -up) and visits to healthcare practitioners external to the study site (eg, 
emergency room, urgent care, primary care physician). Investigators will review unsolicited AEs 
for the o ccurrence of any MAAEs.  
8.4.8.  Adverse Events of Special Interest  
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
Sponsor’s product or program, for which ongoing monitoring and immediate notification by [CONTACT_56864]. Such events may require further investigation to 
characterize and understand them.  
AESI for this protocol are listed in Appendix  5. 
Investigators should report all events which fall into the followi ng categories as an AESI per the 
reporting processes specified in Appendix  3. 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 43 [IP_ADDRESS].  Anaphylaxis  
All suspected cases of anaphylaxis associated with study intervention  administration should be 
recorded as AESIs and reported as an SAE ( Appendix  3), based on criteria for a medically 
important event, unless the event meets other serious criteria. For reporting purposes, a 
participant who displays signs/symptoms consistent with anaphylaxis as shown below should be 
reported as a potential case of anaphylaxis. This is provided as general guidance for Investigators 
and is based on the Brighton Collaboration case definition ( Rüggeberg  et al 2007 ). 
Anaphylaxis is an acute hypersensitivity reaction with multi organ  system involvement that can 
present as, or rapi[INVESTIGATOR_14274], a severe life -threatening reaction. It may occur following 
exposure to allergens from a variety of sources. Anaphylaxis is a clinical syndrome characterized 
by: 
• Sudden  onset AND  
• Rapid progression of signs and symptoms AND  
• Involving 2 or more organ systems, as follows:  
o Skin/mucosal : urticaria (hives), generalized erythema, angioedema, generalized 
pruritus with skin rash, generalized prickle sensation, red and itchy eyes . 
o Cardiovascular : measured hypotension, clinical diagnosis of uncompensated 
shock, loss of consciousness or decreased level of consciousness, evidence of 
reduced peripheral circulation . 
o Respi[INVESTIGATOR_696] : bilateral wheeze (bronchospasm), difficulty breathing, stridor, upper 
airway swelling (lip, tongue, throat, uvula, or larynx), respi[INVESTIGATOR_1506], 
persistent dry cough, hoarse voice, sensation of throat closure, sneezing, 
rhinorrhea . 
o Gastrointestinal : diarrhea, abdominal pain, nausea, vomiting . 
[IP_ADDRESS].  Myocarditis a nd/or Pericarditis  
A case of suspected, probable, or confirmed myocarditis, pericarditis, or myopericarditis should 
be reported as an AESI per Investigator’s medical assessment, even if it does not meet criteria 
per the CDC case definition below. The event  should also be reported as an SAE if it meets 
seriousness criteria ( Section  10.3.2 ). 
The Investigator’s medical judgment must be applied when assessing participan ts reporting 
symptoms concerning for myocarditis and/or pericarditis contained within the CDC case 
definition. Diagnostic evaluation ( eg, EKG, echocardiogram) and laboratory testing 
(eg, troponin) included in the CDC definition ( Table  9) should promptly be obtained if 
considered clinically indicated in any participant with concerning signs/symptoms. Referral to a 
cardiologist should be obtained in those  with positive test results or clinically significant 
symptoms without other identifiable causes. Additional testing and evaluation may be indicated. 
The Investigator will submit any updated myocarditis, pericarditis or myopericarditis case data to 
the Spo nsor within [ADDRESS_504113] findings. Participants with events of 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 44 myocarditis and/or pericarditis will be discontinued from further vaccin ation but should continue 
to be followed in the study for safety as per the protocol.  
An independent CEAC will review all suspected cases of myocarditis, pericarditis, and 
myopericarditis which are reported in ongoing interventional clinical trials per the  CEAC charter 
to determine if they meet CDC criteria for “probable” or “confirmed” events. ( Section  [IP_ADDRESS] ). 
The CDC Working Case Definitions are provided in Appendix  6 as guidance . 
8.5. Pharmacokinetics  
Pharmacokinetic  parameters are not evaluated in this study . 
8.6. Pharmacodynamics  
Pharmacodynamic parameters are not evaluated in this study . 
8.7. Genetics  
 
 
 
 
8.8. Biomarker s 
 
 
 
  
  
  
8.9. Health Economics OR Medical Resource Utilization and Health 
Economics  
Health economics OR Medical resource utilization and health economics parameters are not 
evaluated in this study.  
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 45 9. STATISTICAL CONSIDERATIONS  
This section summarizes the planned statistical analysis strategy  and procedures for the study. 
The details of the statistical analyses will be provided in the SAP, which will be finalized before 
the clinical database lock for the study and treatment unblinding. Ad hoc exploratory analyses, if 
any, will be clearly ident ified in the CSR.  
9.1. Blinding and Responsibility for Analyses  
Blinding during the study will be conducted as described in Section  6.4, with the followi ng 
exceptions:  
• Unblinded personnel (of limited number) will be assigned to vaccine accountability 
procedures and will prepare the study intervention for all participants. These 
personnel will have no study functions other than study intervention management , 
documentation, accountability, preparation, and administration. They will not be 
involved in participant evaluations and will not reveal the identity of the study 
intervention to either the participant or the blinded clinic personnel involved in the 
cond uct of the study unless this information is necessary in the case of an emergency.  
• Unblinded study site staff will administer the study intervention. They will not be 
involved in assessments of any study endpoints.  
• Unblinded site monitors, not involved in other aspects of monitoring, will be assigned 
as the study intervention  accountability monitors. They will have responsibilities to 
ensure that sites are following all proper study intervention  accountability, 
preparation, and administration procedures.  
• An independent unblinded statistical and programming team will perform the 
preplanned primary analysis and the IA (Section  9.6.1 ). Sponsor team members will 
be unblinded for the primary analysis and the IA results and will not communicate the 
results to the blinded Investigators, study site staff, clinical monitors, or  participants.  
• The IST may review unblinded data, as appropriate, to safeguard the interests of 
clinical study participants and to help ensure the integrity of the study.  
The dosing assignment will be concealed by [CONTACT_399971] a secure location that is not accessible or visible to other study site staff. 
Only delegated unblinded study site staff will conduct the injection procedure. Once the injection 
is completed, only the blinded study site staf f will perform further assessments and interact with 
the participants. Access to the randomization code will be strictly controlled at the pharmacy.  
The p rocedure for breaking the blind in the case of a medical emergency is provided in  
Section  6.4. 
9.2. Statistical Hypotheses  
No formal hypotheses will be tested in this study.  
ModernaTX, Inc.  
mRNA -CRID -[ADDRESS_504114] variables.  
With 60 participants in the  study arms, there is an approximately 95%  probability to 
observe at least 1 participant with an AE if the true incidence of the AE is 5%; if the true 
incidence rate is  3%, then the probability to observe an AE is approximately 84%.  
With 30 participants in the  study arms, there is an approximately 95%  probability 
to observe at least 1 participant with an AE if the true incidence of the AE is 9.5%; if the true 
incidence rate is 7.5%, then the probability to observe an AE is approximately 90%.  
9.4. Analysis Sets  
Analy sis sets are listed in Table  5. 
Table  5: Analysis Sets  
Participant Analysis Set  Description  
Randomization Analysis Set  The Randomization Analysis Set consists of all participants who are 
randomized . 
FAS The FAS consists of all randomized participants who receive the 
study intervention. Participants will be included in the study arm to 
which the participant is randomized.  
PPS for Immunogenicity  The PPS consists of all participants in the FAS who comply with the 
injection schedule, comply with the timing of immunogenicity 
blood sampling to have a Baseline (D1) and at least [ADDRESS_504115] the 
immune response.  
The PPS will be used as the primary analysis set for analyses of 
immunogenicity unless otherwise specified.  
Safety Set  Safety Set consists of all participants who receive one  dose of study 
intervention. The Safety Set will be used  for all analyses of safety 
except for the solicited ARs. Participants will be included in the 
study arm corresponding to the study intervention that they actually 
received.  
Solicited Safety Set  The Solicited Safety Set consists of all participants in the  Safety Set 
who contribute any solicited AR data.  
The Solicited Safety Set will be used for the analyses of solicited 
ARs. Participants will be included in the treatment group 
corresponding to the study intervention that they actually received.  
Abbreviation: AR =adverse reaction ; D=day; FAS=full analysis set; PPS =per protocol set . 
9.5. Statistical Analyses  
The SAP for the primary and secondary endpoints will be developed and finalized before 
database lock and will describe the preplanned statistical analysis details , data derivations , the 
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 47 participant populations to be included in the analyses, and procedures for accounting for missing 
data.  
9.5.1.  Baseline Characteristics and Demographics  
Demographic variables (eg, age, sex, race, ethnicity, height, weight, and BMI ) and Baseline 
characteristics will be summarized by [CONTACT_399972].  
Summary statistics (mean and standard deviation for continuous variables, and number and 
percentage for categorical variables) will be provided.  
9.5.2.  Immunogenicity Analyse s 
The analyses of immunogenicity will be based on the PP S. If the number of participants in the 
FAS and PPS differ (defined as the difference divided by [CONTACT_399973]) by [CONTACT_726] 10%, supportive analyses of immunogenicity ma y be conducted using the 
FAS. All immunogenicity analyses will be provided by [CONTACT_30157], at each timepoint unless 
otherwise specified.  
For the immunogenicity endpoints, the GM of antibody titers as measured by [CONTACT_399974] 95% CI at each ti mepoint will be provided by [CONTACT_30157]. The GMFR of antibody 
titers as measured by [CONTACT_399975] 95% CI at each postdose timepoint over 
predose (D1) will be provided by [CONTACT_30157]. The 95% CIs will be calculated based on the 
t-distribution of the log -transformed values and then back -transformed to the original scale. 
Descriptive summary statistics, including median, minimum, and maximum will also be 
provided. For calculation of GMTs reported as below the LLOQ will be replaced by 
0.5 × LLOQ. Val ues that are greater than the ULOQ will be converted to the ULOQ.  
Vaccine seroresponse rate will be provided with a 2 -sided 95% CI using the Clopper -Pearson 
method by [CONTACT_30157]. Vaccine seroresponse is defined as an increase of neutralizing antibody 
titers  from predose below the LLOQ to ≥4 × LLOQ or at least a 4 -fold rise if predose is ≥LLOQ. 
The number and percentage of participants with >2-, 3-fold increases from Baseline (if ≥LLOQ) 
or with >2-, 3-fold increases from LLOQ (if <LLOQ) will also be analyzed with 2 -sided 95% CI 
using the Clopper -Pearson method by [CONTACT_30157], at each postdose timepoint. Further details will 
be described in the SAP.  
9.5.3.  Safety Analyses  
All safety analyses will be based on the Safety Set, except summaries of solicited ARs, which 
will be based on the Solicited Safety Set. All safety analyses will be provided by [CONTACT_46372]. Participants will be included in the study group corresponding to the study intervention 
that they actually received.  
Safety and reactogenicity will be assesse d by [CONTACT_340128] (local and systemic ARs), unsolicited AEs (including any clinically significant 
safety laboratory abnormalities), treatment -related AEs, severe AEs, SAEs, MAAEs, AESIs, and 
AEs leading  to withdrawal from study participation . 
The number and percentage of participants with any solicited local AR, with any solicited 
systemic AR, with any solicited AR during the 7 -day follow -up period after vaccination, and 
with Grade 3 or higher solicited AR will be provided. A 2 -sided 95% exact CI using the 
ModernaTX, Inc.  
mRNA -CRID -[ADDRESS_504116] one IA and  a final CSR for this study . 
9.6.1.  Interim Analysis  
 
 
 
9.6.2.  Final  Clinical Study Report  
The final CSR will include full unblinded analyses of all safety and immunogenicity with  
individual unblinded listings through EoS. 
CCI
CCI
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 49 10. SUPPORTING DOCUMENTATION AND OPE RATIONAL 
CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from  international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences international ethical guidelines . 
o Applicable ICH GCP guidelines . 
o Applicable laws and regulations . 
• The protocol, protocol amendme nts, ICF, IB, and other relevant documents (eg, 
advertisements) must be submitted to an IRB/IEC by [CONTACT_209499]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation exc ept for changes necessary to eliminate an 
immediate hazard to study participants.  
• The Investigator  will be responsible for the following , as applicable : 
o Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC . 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures . 
o Providing oversight of the conduct of the study at the site and adh erence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/[ADDRESS_504117] provide the Sponsor with a commitment to promptly 
update this information if any relevant changes occur  during the course of the investigation and 
for 1 year after completion of the study.  
The Sponsor, the CRO, and the study site are not financially responsible for further testing or 
treatment of any medical condition that may be detected during the screening process. In 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 50 addition, in the absence of specific arrangements, the Sponsor, the CRO, and the study site are 
not financially responsible for further treatment of the disease under study.  
10.1.3.  Informed Consent Process  
• The Investigator or the Investigato r’s representative will explain the nature of the 
study , including the risks and benefits, to the  potential  participant  and answer all 
questions regarding the study.  
• Potential p articipants must be informed that their participation is voluntary. They  will 
be required to sign a statement of informed consent that meets the requirements of 21 
CFR 50, local regulations, ICH guidelines, privacy and data protection  requirements, 
where applicable, and the IRB/IEC or study center.  
• The medical record must include a s tatement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
• Participants must be reconsente d to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant . 
A participant who is rescreened is not required to sign another ICF if the rescreening occurs 
within [ADDRESS_504118] be approved by [CONTACT_1201]/IEC . 
10.1.5.  Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant 
records or datasets that are transferred to the Sponsor will contain the identifier only; 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 51 participant names or any information which would make the participant identifiable 
will not be transferred.  
• The participant must be infor med that their personal study -related data will be used 
by [CONTACT_9324]. The level of disclosure 
must also be explained to the participant  who will be required to give consent for 
their data to be used as describ ed in the informed consent.  
• The participant must be informed that their medical records may be examined by 
[CONTACT_13162], by [CONTACT_6667]/IEC members  and by [CONTACT_399976].  
• The contract between the Sponsor or designee and the study sites may specify 
responsibilities of the parties related to data protection, including handling of data 
security breaches and respective communication and cooperation of the p arties.  
• Information technology systems used to collect, process, and store study -related data 
are secured by [CONTACT_56856], alteration, or unauthorized discl osure or 
access.  
10.1.6.  Committees Structure  
[IP_ADDRESS].  Internal Safety team  
The Sponsor’s independent IST comprise s 3 members, including clinical development 
physicians/clinicians and a safety physician, who are not involved in the study, and will oversee 
the safety of study participants in addition to the clinical development team in charge of the 
study. The IST may p erform unblinded safety data reviews due to safety concerns that arise 
during the study , or as requested on ad hoc bases by [CONTACT_3476].  Details regarding the 
composition, responsibilities, and procedures of the IST will be described in a charter . 
[IP_ADDRESS].  Cardi ac Event Adjudication Committee  
An independent CEAC compris ing medically qualified personnel, including cardiologists, will 
review all suspected cases of myocarditis  and pericarditis, to determine if they meet CDC criteria 
for “probable” or “confirmed” eve nts, which are reported in ongoing interventional clinical trials 
per the CEAC charter ( Gargano et al 2021 ). Any cases that the CEAC assesses as representing 
probable or confirmed cases of myocarditis or pericarditis will be referred to the Sponsor, who 
will then determine if additional action is needed. The CEAC will operate under the rules of an 
approved charter that will be written and reviewed at the organizational meeting of the CEAC. 
Details regarding the CEAC compositio n, responsibilities, procedures, and frequency of data 
review will be defined in the charter.  
10.1.7.  Dissemination of Clinical Study Data  
The Sponsor shares information about clinical studies and results on publicly accessible 
websites, based on international and  local legal and regulatory requirements, and other clinical 
study disclosure commitments established by [CONTACT_13174]. These 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 52 websites include clinicaltrials.gov, European Union clinical trial register, and some national 
registries.  
10.1.8.  Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or eCRF s unless 
transmitted to the Sponsor or designee electronically ( eg, laboratory data). The 
Investigator is responsible for verifying that data entries are a ccurate and correct by 
[CONTACT_1189].  
• Guidance on completion of CRFs will be provided in the CRF Completion 
Guidelines . 
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency insp ections and provide direct access to source documents.  
• Monitoring details describing strategy , including definition of study critical data 
items and processes (eg, risk -based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk-based monitoring), 
methods, responsibilities , and requirements, including handling of noncompliance 
issues and monitoring techniques (central, remote, or on -site monitoring) are provided 
in the clinical monitoring  plan. 
• The Spons or or designee is responsible for the data management of this study , 
including quality checking of the data.  
• The Sponsor assumes accountability for actions delegated to other individuals 
(eg, CRO s). 
• Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_13177] [ADDRESS_504119] artic le for investigation unless local regulations or institutional policies require a 
longer retention period. No records may be destroyed during the retention period 
without the written approval of the Sponsor. No records may be transferred to another 
locatio n or party without written notification to the Sponsor.  
10.1.9.  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
Investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The Investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• Definition of what constitutes source data and its origin can be found in Source Data 
Agreement . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 53 • The Investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF.  
• The Sponsor or designee will perform monitoring  to confirm that data entered into the 
CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.10.  Study and Site Start and Closure  
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the first site open  and will be the study start date.  
Study/Site Termination  
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been co llected and a study  site closure visit has been performed.  
The Investigator may initiate study  site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure  of a study site by [CONTACT_9330]:  
For study termination:  
• Discontinuation of further study intervention development . 
For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor ’s procedures, or GCP guidelines . 
• Inadequate  or no  recruitment  (evaluated after a reasonable amount of time)  of 
participants by [CONTACT_737] . 
• Total number of participants included earl ier than expected.  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any CRO (s) used in the study of the 
reason for termination or suspension, as specifi ed by [CONTACT_1214]. The 
Investigator shall promptly inform the participant  and should assure appropriate participant  
therapy and/or follow -up. 
10.1.11.  Publication Policy  
• The results of this study may be published or presented at scientifi c meetings. If this 
is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the 
ModernaTX, Inc.  
mRNA -CRID -[ADDRESS_504120] proprietary 
information and to provide comments.  
• The Sponsor will comply with the requireme nts for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating Inv estigator will be designated by [CONTACT_231692].  
• Authorship will be determined by [CONTACT_14346].  
  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 55 10.2. Appendix 2: Clinical Laboratory Tests  
• The tests detailed in Table  6 will be performed by [CONTACT_2237] . 
• Local laboratory results are only required in the event that the central laboratory 
results are no t available in time for either study intervention administration and/or 
response evaluation. If a local sample is required, it is important that the sample for 
central analysis is obtained at the same time. Additionally, if the local laboratory 
results are  used to make either a study intervention decision or response evaluation, 
the results must be recorded.  
• Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section  5. 
• Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_347847].  
• Investigators must document their review of each laboratory safety report.  
Table  6: Protocol -required Safety Laboratory Tests  
Laboratory Tests  Parameters  
Pregnancy Testing  • Highly sensitive serum or urine  hCG pregnancy test (as needed for 
POCBP )1 
Other Screening Tests • FSH and estradiol (as needed in PONCBP  only)  
Abbreviations: FSH= follicle -stimulating hormone ; hCG= human chorionic gonadotropin ; IEC= independent ethics 
committee ; IRB= institutional review board ; POCBP=p erson of childbearing potential ; PONCBP=person of 
nonchildbearing  potential . 
NOTES:  
[ADDRESS_504121] for the protocol unless serum testing is required by [CONTACT_112249]/IEC.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 56 10.3. Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1.  Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.  
• NOTE: An AE can therefore be any  unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention . 
Definition of Unsolicited and Solicited AE  
• An unsolicited AE is an AE that was not solicited using a participant diary and that is 
communicated by a participant who has signed the informed consent. Unsolicited 
AEs include serious and nonserious AEs.  
• Potential unsolicited AEs may be medically attended (ie, symptoms or illnesses 
requir ing a hospi[INVESTIGATOR_059], emergency room visit, or visit to/by a healthca re 
provider). The participant will be instructed to contact [CONTACT_14347](s ), as well as any events that, though not medically 
attended,  are of participant concern. Detailed information about reported unsolicited 
AEs will be collected by [CONTACT_14348]’s 
records.  
• Unsolicited AEs that are not medically attended nor perceived as a concern by [CONTACT_399977].  
• Solicited AEs are predefined local (at the injection site) and systemic events for 
which the participant is specifically ques tioned, and which are noted by [CONTACT_14350].  
Events Meeting the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measu rements), 
including those that worsen from Baseline , considered clinically significant in the 
medical and scientific judgment of the Investigator  (ie, not related to progression of 
underlying disease , or more severe than expected for the participant’s cond ition). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition . 
• New condition detected or diagnosed after study intervention administration even 
though it may have been p resent before the start of the study . 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 57 • Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per s e will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
Events not Meeting the AE Definition  
• Medical or surgical procedure (eg, end oscopy, appendectomy): the condition that 
leads to the procedure is the AE . 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) . 
• Anticipated day -to-day fluctuations of pre -existing disease(s)  or condition(s) present 
or detected at the start of the study that do not worsen . 
10.3.2.  Definition of SAE  
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of 
the criteria listed:  
a. Results in death . 
b. Is life -threatening . 
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires in patient hospi[INVESTIGATOR_1081] . 
• In general, hospi[INVESTIGATOR_12994]  (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_399951]/or treatm ent that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. 
If a complication prolongs hospi[INVESTIGATOR_9236], the 
event is serious. When  in doubt as to whether hospi[INVESTIGATOR_14275], the AE should be considered serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from Baseline is not considered an AE.  
d. Results in persistent or s ignificant disability/incapacity . 
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday li fe functions but do not constitute a substantial disruption . 
e. Is a congenital anomaly/birth defect . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 58 f. Other situations:  
• Medical or scientific judgment should be exercised by [CONTACT_399978] -threatening or result in death or 
hospi[INVESTIGATOR_399952]. These 
events should usually be considered serious.  
o Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home  for allergic bronchospasm, blood dyscrasias , 
convulsions not resulting in hospi[INVESTIGATOR_059], or development of intervention  
dependency or intervention  abuse . 
10.3.3.  Definition of MAAE  
A MAAE is an AE that leads to a USV  to a healthcare practitioner. This would include visits to a 
study site for unscheduled assessments not required per protocol (eg, rash assessment, abnormal 
laboratory follow -up) and visits to healthcare practitioners external to the study site (eg, 
emergency room, urgent care, primary care physician).  
10.3.4.  Definition of AESI  
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
Sponsor’s product or program, for which ongoing monitoring and immediate notification by [CONTACT_14353]. Such events may require further investigation to 
characterize and understand them . 
The AESIs defined for this protocol can be found in Section  10.5. 
10.3.5.  Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics 
reports) related to the event.  
• The Investi gator  will then record all relevant AE/SAE information . 
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the Sponsor or designee  in lieu of the  EDC entry . 
• There may be instances when copi[INVESTIGATOR_399953] . In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_14278] . 
• The Investigator  will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 59 Assessment of Intensity  
The Investigator  will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to one of the following categories:  
• Mild:  
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic interven tion. The event does not generally interfere with usual activities 
of daily living.  
• Moderate:  
A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.  
• Severe:  
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
The Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventative Vaccine Clinical Trials ( DHHS 2007 ) will be used to categorize local and systemic 
reactogenicity events ( solicited ARs ), clinical laboratory test results, and vital sign measurements 
observed during this trial. The intensity grading scale used in this trial is presented in Table  7. 
Table  7: Adult and Adolescent Solicited Adverse Reactions and Grades  
Reaction  Grade  0 
(None)  Grade  1 
(Mild)  Grade  2 
(Moderate)  Grade  3 
(Severe)  Grade  4 
(Life -
threatening)  
Local  
Injection site pain  None  No interference 
with activity  Some interference 
with activity  Prevents daily 
activity  Requires 
emergency 
room visit or 
hospi[INVESTIGATOR_14279] (redness)  <25 mm/ 
<2.5 cm 25-50 mm/ 
2.5-5 cm 51-100 mm/ 
5.1-10 cm >100 mm/ 
>10 cm Necrosis or 
exfoliative 
dermatitis  
Injection site 
swelling/induration 
(hardness)  <25 mm/ 
<2.5 cm 25-50 mm/ 
2.5-5 cm 51-100 mm/ 
5.1-10 cm >100 mm/ 
>10 cm Necrosis  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 60 Reaction  Grade  0 
(None)  Grade  1 
(Mild)  Grade  2 
(Moderate)  Grade  3 
(Severe)  Grade  4 
(Life -
threatening)  
Axillary (underarm) 
swelling or 
tenderness 
ipsilateral to the 
side of injection  None  No interference 
with activity  Some interference 
with activity  Prevents daily 
activity  Requires 
emergency 
room visit or 
hospi[INVESTIGATOR_399954]  
(muscle aches all 
over body)  None  No interference 
with activity  Some interference 
with activity  Prevents daily 
activity  Requires 
emergency 
room visit or 
hospi[INVESTIGATOR_14281]  
(joint aches in 
several joints)  None  No interference 
with activity  Some interference 
with activity  Prevents daily 
activity  Requires 
emergency 
room visit or 
hospi[INVESTIGATOR_14282]/vomiting  None  No interference 
with activity or 
1-2 epi[INVESTIGATOR_1841]/ 
24 hours  Some interference 
with activity or 
>2 epi[INVESTIGATOR_1841]/24  hours  Prevents daily 
activity, 
requires 
outpatient 
intravenous 
hydration  Requires 
emergency 
room visit or 
hospi[INVESTIGATOR_399955] (oral)  <38.0°C  
<100.4°F  38.0-38.4°C  
100.4 -101.1°F  38.5-38.9°C  
101.2 -102.0°F  39.0-40.0°C  
102.1 -104.0°F  >40.0°C  
>104.0°F  
Note: Events listed above but starting >[ADDRESS_504122] study  intervention will be recorded in EDC . Causality for each 
event will be determined per assessment by [CONTACT_737].  
Source: Modified from the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials ( DHHS 2007 ). 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 61 Assessment of Causality  
• The Investigator  is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE . The Investigator  will use clinical judgment to 
determine the relationship.  
• Not related:  There is not a reasonable possibility of a relation ship to the study 
intervention . Participant did not receive the study intervention  OR temporal sequence 
of the AE onset relative to administration of the study intervention  is not reasonable 
OR the AE is more likely explained by [CONTACT_14354] . 
• Related:  There is a reasonable possibility of a relationship to the study intervention . 
There is evidence of exposure to the study intervention . The temporal sequence of the 
AE onset relative to the administration of the study intervention  is reasonable. The 
AE is more likely explained by [CONTACT_46364].  
• For causality assessment, t he Investigator  will also consult the IB and/or product 
information, for marketed products.  
• The Investigator  must review and provide  an assessment of causality for each 
AE/SAE and document this in the medical notes.  There may be situations in which an 
SAE has occurred and the Investigator  has minimal information to include in the 
initial report to the Sponsor  or designee . However, it i s very important that the 
Investigator  always make an assessment of causality for every event before the initial 
transmission of the SAE data to the Sponsor  or designee . 
• The Investigator  may change their opi[INVESTIGATOR_9242] -up 
informati on and send a n SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Follow -up of AEs and SAEs  
• The Investigator is obligated to perform or arrang e for the conduct of supplemental 
measurements and/or evaluations  as medically indicated or as requested by [CONTACT_14356]/or causality of the AE or SAE as fully 
as possible. This may include additional laboratory tests  or investigations, 
histopathological examinations, or consulta tion with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period, the Investigator will provide the Sponsor or designee  with a copy of any 
postmortem findings including histopathology.  
• New or updated information will be recorded in the originally submitted documents.  
• The Investigator will submit any updated SAE data to the Sponsor or designee  within 
24 hours of receipt of the information.  
10.3.6.  Reporting of SAEs /AESI  
NOTE: AESI will be reported in the same way as SAEs  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 62 SAE Reporting to the Sponsor or designee  via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to  the Sponsor or designee  will be the 
electronic data collection tool  (ie, EDC) . 
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed at a given site, the electronic data collection tool will be 
taken offline to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study par ticipant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken offline, then the site can report this information on a paper SAE form (see next 
section) . 
SAE Reporting to the Sponsor or designee  via Paper Data Collection Tool  
• Email transmission of the SAE paper data collection tool is the preferred method to 
transmit this information to the Sponsor . 
• Initial notification via email or fax  does not replace the need for the Investigator  to 
complete and sign the electronic SAE data collection tool  within the designated 
reporting timeframes.  
• SAE reports  should be emailed to [EMAIL_1060].  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 63 10.4. Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions  
Person  of Childbearing Potential  
Persons AFAB are  considered POCBP (fertile)  following menarche : 
• From the time of menarche until becoming pos tmenopausal unless permanently sterile . 
• A postmenopausal state is defined as no menses for [ADDRESS_504123] 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment.  
• Permanent sterilization methods (for the purpose of this study) include:  
o Documented hysterectomy . 
o Documented bilateral salpi[INVESTIGATOR_1656] . 
o Documented bilateral oophorectomy . 
o For individuals with permanent infertility due to an alternate medical cause other 
than the above,  (eg, Mullerian agenesis, androgen insensitivity, gonadal 
dysgenesis), Investigator discretion should be applied to determining study entry.  
Note:  Documentati on can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
If fertility is unclear ( eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first  dose of study intervention, additional evaluation should be considered.  
Person  of Nonchildbearing Potential  
Persons AFAB  in the following categories are considered PONCBP : 
1. Premenopausal persons AFAB  with permanent infertility due to one  of the following:  
a. Documented hysterectomy . 
b. Documented bilateral salpi[INVESTIGATOR_1656] . 
c. Documented bilateral oophorectomy . 
d. For individuals with permanent infertility due to an alternate medical cause other than 
the above,  (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
Investigator discretion should be applied to determining study entry.  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 64 Note : Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination,  or medical history interview.  
2. Postmenopausal persons AFAB : 
a. A postmenopausal state is defined as no menses for 12  month s without an alternative 
medical cause.  
i. A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in wom en not using hormonal contraception or hormonal 
replacement therapy. However, in the absence of 12  month s of amenorrhea, 
confirmation with more than one FSH measurement (>40 IU/L or mIU/mL) is 
required.  
ii. Persons AFAB  on HRT and whose menopausal status is in  doubt must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment . 
10.4.2.  Contraception Guidance  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when 
used consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulation . 
• IUD. 
• IUS. 
• Bilateral tubal occlusion . 
• Azoospermic partner (vasectomized or due to a medical cause) . 
• Azoospermia is a highly effective contraceptive method provided that the partner is the sole 
sexual partner of the POCBP  and the absence of sperm has been confirmed. If not, an 
additional highly effective method of contraception should be used. Spermatogen esis cycle is 
approximately 90  days. 
Note: documentation of azoospermia for a participant can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  
Highly Effective Methodsb That Are  User Dependent Failure rate of <1% per year when used 
consistently and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition 
of ovulation : 
Oral. 
Intravaginal . 
Transdermal . 
Injectable . 
Progestogen -only hormone contraception associated with inhibition of ovulation : 
Oral. 
Injectable . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 65 CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when 
used consistently and correctly.  
Sexual abstinence . 
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.  
Effective Methods That Are Not Considered Highly Effective Failure rate of ≥1% per year when 
used consistently and correctly.  
• Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary mode of action . 
• External or intern al condom with or without spermicide . 
• Cervical cap, diaphragm, or sponge with spermicide . 
• A combination of external condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods)c. 
a. Contraceptive use should be consistent with local regulations regarding the use of contraceptive 
methods for those participating in clinical studies.  
b. Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_399956]. 
c. Considered effective, but not highly effective - failure rate of ≥1% per year.  
Note: Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus 
interruptus), spermicides only, and LAM are not acceptable methods of contrace ption. External  
condom and internal  condom should not be used together (due to risk of failure from friction).  
Abbreviations: IUD=intrauterine device ; IUS=intrauterine hormone -releasing system ; LAM= lactational amenorrhea 
method ; POCBP =person of childbearing potential . 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 66 10.5. Appendix  5: Adverse Event of Special Interest  
Investigators should report all events that fall into the categories presented in Table  [ADDRESS_504124] in vaccine safety surveillance as per the Brighton Collaboration and Safety 
Platform for Emergency Vaccines  or the vac cine platform . 
Table  8: Adverse Events of Special Interest  
Medical Concept  Additional Notes  
Thrombocytopenia  • Platelet counts <125 × 109. 
• Including but not limited to immune thrombocytopenia, platelet 
production decreased, thrombocytopenia, thrombocytopenic 
purpura, thrombotic thrombocytopenic purpura, or HELLP 
syndrome . 
New onset of or worsening 
of the following neurologic 
diseases:  • Guillain -Barre  Syndrome . 
• ADEM . 
• Idiopathic peripheral facial nerve palsy (Bell’s palsy) . 
• Seizures including but not limited to febrile seizures and/or 
generalized seizures/convulsions . 
Anaphylaxis  • Anaphylaxis  associated with IP administration  as defined per 
protocol  in Section  [IP_ADDRESS] . 
• Follow reporting procedures in Section  10.3.6 . 
Myocarditis/Pericarditis  • Myocarditis . 
• Pericarditis . 
• Myopericarditis . 
Abbreviations: ADEM= acute disseminated encephalomyelitis ; HELLP =hemolysis, elevated liver enzymes and low 
platelets ; IP=investigational product . 
  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 67 10.6. Appendix 6: CDC Working Case Definitions of Pericarditis, 
Myocarditis, and Myopericarditis Occurring After Receipt of 
COVID -19 mRNA Vaccines  
The CDC Working Case Definitions of probable and confirmed myocarditis, pericarditis, and 
myopericarditis ( Gargano et al 2021 ) are provided i n Table  9 as guidance.  
Table  9: Case Definiti ons of Probably and Confirmed Myocarditis, Pericarditis, and 
Myopericarditis  
Condition  Definition  
Acute 
myocarditis  Probable case  Confirmed case  
Presence of ≥1 new or worsening of 
the following clinical symptoms:*  
• Chest pain, pressure, or discomfort.  
• Dyspnea, shortness of breath, or 
pain with breathing.  
• Palpi[INVESTIGATOR_814].  
• Syncope.  Presence of ≥1 new or worsening of the 
following clinical symptoms:*  
• Chest pain, pressure, or discomfort.  
• Dyspnea, shortness of breath, or pain 
with breathing.  
• Palpi[INVESTIGATOR_814].  
• Synco pe. 
OR, infants and children aged 
<[ADDRESS_504125] ≥2 of the 
following symptoms:  
• Irritability.  
• Vomiting.  
• Poor feeding.  
• Tachypnea.  
• Lethargy.  OR, infants and children aged <[ADDRESS_504126] ≥2 of the following 
symptoms:  
• Irritability.  
• Vomiting.  
• Poor feeding.  
• Tachypnea.  
• Lethargy.  
AND  
≥1 new finding of  
• Troponin level above upper limit 
of normal (any type of troponin).  
• Abnormal electrocardiogram (ECG 
or EKG) or rhythm monitoring 
findings consistent with 
myocarditis§. 
• Abnormal cardiac function or wall 
motion abnormalities on 
echocardiogram.  
• cMRI findings consistent with 
myocarditis¶.  AND  
≥1 new finding of  
• Histopathologic confirmation of 
myocarditis†. 
• cMRI findings consistent with 
myocarditis in the presence of 
troponin level above upper limit of 
normal (any type of troponin).  
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 68 Condition  Definition  
AND  
• No other identifiable cause of the 
symptoms and findings.  AND  
• No other identifiable cause of the 
symptoms and findings.  
Acute 
pericarditis**  Presence of ≥2 new or worsening of the following clinical features:  
• Acute chest pain††. 
• Pericardial rub on exam.  
• New ST -elevation or PR -depression on EKG.  
• New or worsening pericardial effusion on echocardiogram or MRI.  
Myopericarditis  This term may be used for patients who meet criteria for both myocarditis and 
pericarditis.  
Abbreviations: AV=atrioventricular; CDC =Centers for Disease Control and Prevention; CEAC =Cardiac Event 
Adjudication Committee; cMRI =cardiac magnetic resonance imaging; ECG or EKG =electrocardiogram; 
MRI =magnetic resonance imaging.  
Note: An independent CEAC comprising  medically qualified personnel, including cardiologists, will review 
suspected cases of  myocarditis, pericarditis, and myopericarditis to determine if they meet Center for Disease 
Control  and Prevention  criteria for “pro bable” or “confirmed” events  (Gargano et al 2021 ), and provide the 
assessment to the Sponsor. The CEAC members will be blinded to study treatment. Details regarding the CEAC 
composition, responsibilities, procedures, and frequency of data review will be defined in the CEAC charter.  
* Persons who lack the listed symptoms but who meet other criteria may be classified as subclinical myocarditis 
(probable or confirmed).  
† Using the Dallas criteria ( Aretz et al 1987 ). Autopsy  cases may be classified as confirmed clinical myocarditis on 
the basis of meeting histopathologic criteria if no other identifiable cause.  
§ To meet the ECG or rhythm monitoring criterion, a probable case must include at least one o f 1) ST -segment or 
T wave abnormalities; 2) Paroxysmal or sustained atrial, supraventricular, or ventricular arrhythmias; or 3) AV 
nodal conduction delays or intraventricular conduction defects.  
Using either the original or the revised Lake Louise criteria . 
https://www.sciencedirect.com/science/article/pii/S0735109718388430?via%3Dihubexternal icon . 
** https://academic.oup.com/eurheartj/article/36/42/2921/2293375external icon . 
†† Typi[INVESTIGATOR_14284], deep inspi[INVESTIGATOR_1516], or coug h, and relieved by [CONTACT_46391], although other types of chest pain might occur.  
Reference: ( Gargano et al 2021 ). 
ModernaTX, Inc.  
mRNA -CRID -004 Clinical Study Protocol  mRNA -CRID  
Confidential  Page 69 11. REFERENCES  
Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, et al. 
Myoca rditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 
1987;1:3 -14. 
Department of Health and Human Services (DHHS), Food and Drug Administration, Center for 
Biologics Evaluation and Research (US). Guidance for industry: Toxicity g rading scale for 
healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 
September  2007 [cited 202 2 Jun 23]. Available from: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInfor
mation/Guidances/Vaccines/ucm091977.pdf.  
Department of Health and Human Services . Conduct of Clinical Trials of Medical Products 
During the COVID -19 Public Health Emergen cy: Guidance for Industry, Investigators, and 
Institutional Review Boards. March 2020 [updated 2021 Jan 27; cited 2021 Mar 18] [38 screens]. 
Available from: https://www.fda.gov/media/136238/download. 2020.  
Gargano JW, Wallace M, Hadler SC, Langley G, Su JR , Oster ME, et al. Use of mRNA 
COVID -19 Vaccine After Reports of Myocarditis Among Vaccine Recipi[INVESTIGATOR_840]: Update from the 
Advisory Committee on Immunization Practices - [LOCATION_002], June 2021. MMWR Morb 
Mortal Wkly Rep 2021;70(27):977 -82. 
 
 
Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al.  Brighton 
Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data 
collection, analysis, and presentation of immunization safety data. Vaccine. 2007 Aug 
1;25(31):5675 -84. 
 
 
 
CCI
CCI